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Janice L. Farlow 
FAMILY STUDIES IN WHOLE EXOME AND GENOME SEQUENCING 
 
Population genetics has been revolutionized by the advent of high-throughput 
sequencing (HTS) methods in the 21st century. Modern day sequencers are now 
capable of sequencing entire exomes and genomes at unprecedented speed and 
accuracy. An explosion of bioinformatics software and data analysis tools now 
makes sequencing accessible for gene discovery in both rare Mendelian and 
complex disease. Family-based sequencing studies in particular have great 
potential for elucidating the genetic basis for many more diseases. 
 
We apply both whole exome and genome sequencing to three different cases of 
familial disease: intracranial aneurysm (IA), Parkinson disease (PD), and X-
linked ataxia dementia (XLAD). IA and PD are both common, complex traits that 
inflict a devastating disease burden worldwide, mostly due to few effective 
therapeutic interventions. Little of the heritability of both IA and PD has been 
explained to date, especially as it relates to the impact of rare variation on 
disease. XLAD is an extremely rare neurological disease described thus far in 
one kindred. Although promising results have been achieved through previous 
genetic study designs, the causative gene has not yet been identified. For all 
three diseases, HTS offers an opportunity to explore the role of rare variation in 
disease pathogenesis. In each study, we explore the opportunities and 
challenges of family-based HTS for different disease models. The work 
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presented herein contributes effective practices for study design, analysis, and 
interpretation in a rapidly growing field still replete with questions about how best 
to implement HTS in studying familial disease. 
 
Tatiana Foroud, Ph.D., Chair 
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INTRODUCTION 
 
A brief history of population genetics 
Since the days of Hippocrates, collecting and analyzing a family’s history of 
disease has been an integral part of the practice of medicine. Physicians knew 
that a family medical history can indicate a higher risk for certain diseases and 
conditions, even if the causative mechanism for the risk was unknown. It was not 
until the 1800’s, when Gregor Mendel completed his meticulous breeding 
experiments with sweet peas, that the laws of hereditary genetics began to be 
defined. When his work was rediscovered a century later, modern genetics was 
born, and scientists quickly began to investigate Mendelism as it applied to 
human families with disease. 
 
In the middle of the 20th century, principles of genetic linkage and recombination 
were explored, leading to the ability to map chromosomes. This enabled 
scientists to conduct linkage studies, in which genetic regions harboring 
causative mutations could be mapped by observing the segregation patterns of 
disease with the inheritance of genetic markers. Linkage analysis was very 
successful in mapping a number of monogenic diseases, including cystic 
fibrosis1-4 and Huntington’s disease.5 This methodology, however, is not 
successful at exploring all disease traits. For instance, large multiplex families 
required for robust linkage signals sometimes do not exist for extremely rare 
diseases that are fatal well before child-bearing years. Additionally, linkage 
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studies conducted for complex traits, such as diabetes and schizophrenia, 
sometimes seemed to conflict with previous findings for the same trait.6-8 The 
heterogeneity of complex traits, which are caused by a combination of multiple 
genetic and/or environmental factors, limits the statistical power of linkage 
analysis in families. Furthermore, for those linkage studies that do reach 
statistical significance, the implicated interval may contain hundreds of genes, 
requiring intensive molecular work to identify the causative gene. 
 
Candidate gene studies constitute another approach for studying human disease. 
After forming a hypothesis that a particular candidate gene is involved in the 
underlying pathophysiology of a disease, researchers can statistically test 
whether a particular allele of the gene is more frequently observed in cases than 
controls. Thus, population-based samples can be used instead of the unique 
families required for robust linkage mapping. Additionally, greater statistical 
power to detect genes of small effect sizes can be obtained through candidate 
gene association tests than through linkage analysis.9 While most candidate 
gene studies have focused on common variation, the most notable consistent 
finding of which has been the APOE association with Alzheimer’s disease,10 
some studies have also been utilized to explore rare variation.11,12 Despite some 
promising findings, candidate gene approaches have faced criticisms for poor 
replication of findings13-15 and for the significant limitation of requiring a priori 
knowledge about disease mechanisms.  
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With the development of genome-wide single nucleotide polymorphism (SNP) 
arrays, unbiased genome-wide association (GWA) studies became possible. 
GWA studies, which became popular starting in 2005, began to elucidate many 
common variants of smaller effect size important in complex diseases.16 While 
many GWA studies have focused on large cohorts of unrelated individuals, some 
have also explored familial diseases.17 Many GWA studies, however, suffer from 
the inability to narrow down an associated genetic region to a causative mutation, 
and the necessity to gather large samples numbering in the tens of thousands 
presents challenges for many disease models. 
 
Findings from candidate gene, linkage, and GWA studies together have identified 
the genetic basis for a small percentage of diseases, and for some traits, they 
have accounted for only a portion of the estimated heritability of the disease. In 
particular, linkage studies have been able to explore rare variants with large 
effect sizes (Figure 1). GWA studies, on the other hand, are better powered to 
find common variation, or variants found in at least 5% of the general population, 
with lower effect sizes. Thus, researchers have suggested that some of the 
remaining heritability lies with rare variation of moderate to high effect sizes.18-22 
Such variation cannot be explored effectively using historical population genetics 
approaches, but this all changed with the genesis of high-throughput sequencing 
(HTS). 
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Figure 1. Genetic variant frequencies and effect sizes. Manolio et al, 2009.23 
 
 
Advent of high-throughput sequencing 
In the 1970’s, researchers ascertained the first DNA sequences, paving the way 
for the sequencing of the first genome in 1977.24 The Sanger sequencing 
method24,25 that made this advance possible remained the primary way to 
sequence DNA until the 21st century. In this method, a labeled primer is annealed 
to a known segment of DNA juxtaposed to the unknown sequence of interest. 
Catalytic polymerization reactions then occur in four different tubes, each 
containing a different nucleotide, until the random addition of a specially-labeled 
chain-terminator nucleotide. The separation of the resultant fragments of DNA on 
a polyacrylamide gel by fragment size then allows the researcher to determine 
the nucleotide sequence. This basic technique with modifications, coupled with 
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the development of the polymerase chain reaction (PCR) in the 1980’s, 
eventually led to the sequencing of the first human genome in 2001.26 
 
In 2004, HTS was introduced as ‘next-generation’ sequencing. HTS, which relies 
on parallel sequencing of millions of small stretches of DNA, exponentially 
increased the number of bases that could be sequenced given a finite cost and 
timeframe. Competition and technological advances drove the rapid evolution of 
commercially available sequencers. At the time of the work presented herein, 
Illumina products dominated much of the HTS market. Like traditional Sanger 
sequencing, this technology (Figure 2) first sonicates genomic DNA into small 
fragments, which are ligated to adapters. After hybridization to a flow cell, the 
fragments are amplified creating clusters of fragments with the same nucleotide 
sequence. The complementary strand of DNA is removed, and the sequencer 
then adds fluorescently-labeled nucleotides sequentially and visually records the 
resulting fluorescence. The produced image is then reverted to a short string of 
nucleotide sequence, referred to as a sequencing read. After the sequencing run 
is complete, these reads and accompanying quality metrics can then be 
processed using a number of bioinformatics methods, which are described later.
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Figure 2. High-throughput DNA sequencing on the Illumina platform. 
Churko et al, 2013.27 
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Combined with the development of bioinformatics methods to leverage the 
reference genome sequence, HTS became feasible for researchers around the 
world. Techniques were developed not only for sequencing and detecting 
variation for whole genomes, but also for targeted parts of the genome and for 
more complex genetic features. Whole exome sequencing (WES), for instance, 
provides sequence data for just the exome, or the coding portion of the genome. 
Although the exome only comprises 1% of the genome, most mutations 
associated with Mendelian disease to date have been found in the coding portion 
of the genome.28-31 Thus, many researchers interested in studying sequence 
variation in disease have opted for the sequencing of more individuals using the 
more cost-effective WES approach instead of WGS.32 The transcriptome, or the 
RNA produced from DNA, can also be sequenced through HTS. Variation in the 
transcriptome can provide clues about alternative splicing, differential expression, 
gene fusion events, and functional non-coding RNAs. A wide variety of 
epigenomic data can also be obtained through HTS, allowing researchers an 
unprecedented genome-wide perspective on effects and mechanisms of 
transcriptional control. A sample of possible applications of HTS is listed in Table 
1. 
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Table 1. Applications of high-throughput sequencing. Adapted from 
Shendure et al, 2012.33 FAIRE = formaldehyde-assisted isolation of regulatory 
elements; MAINE = MNase-assisted isolation of nucleosomes; ChIP = chromatin 
immunoprecipitation; RIP = RNA-binding protein immunoprecipitation; CLIP = 
cross-linking immunoprecipitation; HITS = high-throughput sequencing of RNA 
isolated by CLIP; ChIA-PET = chromatin interaction analysis paired-end tag 
Method Feature Examined 
DNA-Seq Genome 
Targeted DNA-Seq Subset of a genome, e.g. whole exome 
sequencing 
Methyl-Seq Sites of DNA methylation 
DNase-Seq, Sono-Seq, 
FAIRE-Seq 
Active regulatory chromatin 
MAINE-Seq Histone-bound DNA 
ChIP-Seq Protein-DNA interactions 
RIP-Seq, CLIP-Seq, HITS-
CLIP 
Protein-RNA interactions 
RNA-Seq  Transcriptome 
Hi-C Three-dimensional genomic structure 
ChIA-PET Long-range interactions mediated by a 
protein 
Ribo-Seq Ribosome-protected mRNA fragments 
(mRNA under active translation) 
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In 2009, two landmark reports of the use of WES for gene discovery were 
published.34,35 In the first study, WES was applied to 10 unrelated individuals 
affected by Kabuki syndrome, a rare multi-system disorder that has only been 
reported in about 400 cases worldwide.34 A careful review of the variants 
identified and comparison of them to public databases and control exomes 
eventually led to the identification of MLL2 as the causative gene. In the second 
study, the exomes of two siblings and two unrelated individuals affected by Miller 
syndrome were sequenced.35 A similar method of retaining only rare variants, 
coupled with application of different inheritance models eventually singled out 
DHODH as the culpable gene. In both of these cases, Ng and colleagues were 
able to identify not only the genetic region linked with a disease, but the exact 
variation causing the disease as well. This was accomplished using only a few 
individuals, unlike the large multi-generational pedigrees required for linkage 
analysis or the thousands of individuals necessary for statistically robust GWA 
studies. 
 
Within the next few years, the costs for sequencing and the storage of large 
datasets fell rapidly, and large collaborative efforts like the 1000 Genomes 
Project36 produced resources that enabled small and large research efforts alike 
to conduct their own HTS experiments. To date, the genetic basis of over 100 
rare Mendelian30 and complex diseases37 has been discovered using WES and 
whole genome sequencing (WGS).38 
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A general framework for analysis of sequencing studies 
The bioinformatics community has developed thousands of techniques to make 
these discoveries possible. After sample preparation and sequencing (Figure 2) 
the numerous steps of bioinformatics processing can largely be boiled down to 
the general categories of alignment and variant detection, with measures taken 
for assessing quality throughout the process. 
 
Alignment consists of matching each read to the reference genome. A series of 
steps are taken to ensure that excess mismatches at particular bases, within 
reads, and within regions are reviewed; duplicate reads are removed; and 
recalibration is performed for insertion/deletions (indels) and other types of 
structural variation.  Although Burrows-Wheeler Aligner (BWA) is often the 
aligner of choice and is used throughout the present work, dozens of alignment 
programs exist and can be employed for different kinds of scenarios. Additionally, 
some software also permits de novo assembly, where a reference genome is not 
used in aligning the sequence. Such programs thus can be used to identify novel 
sequence or in species where a reference genome does not exist. 
 
A number of programs exist for the next stage in data processing, or variant 
calling. The most frequently used programs currently can robustly detect single 
nucleotide variants (SNVs) and small indels. Some of the newer programs 
designed to identify larger indels and other types of structural variation are still 
being vetted by the bioinformatics community. Variant detection software typically 
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looks at the sequencing reads that span each position (or a stretch of bases for 
structural variation) to identify whether nucleotide calls for some or all of the 
reads differ from the reference genome. Some programs also examine 
haplotypes, or a collection of linked alleles, to increase the quality of variant calls; 
such programs are generally helpful for most sequencing studies but may not be 
the variant caller of choice when looking at extremely rare variants. Many 
programs recalibrate their variant calls based on a number of factors, sometimes 
dictated by the algorithm employed and other times chosen through machine 
learning approaches. 
 
Throughout both the alignment and variant detection steps, various methods of 
quality control exist. General quality metrics such as sequencing depth and 
percentage of bases covered at particular depths can help determine if samples 
need to be re-sequenced. The number of different types of variants per sample, 
as well as statistics such as the transition to transversion ratio and the 
percentage of variants previously identified, can be compared to normally 
expected numbers and ratios. Even with a number of different quality metrics, 
typically the alignment and quality sequencing reads of variants of interest should 
be reviewed using inspection software, and many groups validate the variants 
using genotyping arrays or the traditional Sanger sequencing method. Some 
basic quality control measures are reviewed by Do and colleagues.39 
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After variant detection and quality control measures, a typical WES experiment 
will generate over 20,000 exonic SNVs per individual.30 Of these variants, 
10,000-12,500 will typically be synonymous variants, 9,500-12,000 are expected 
to be missense, and 100-200 will be splice altering or stop variants.39 WGS, on 
the other hand, will typically yield over 3 million SNVs per individual.40 A typical 
healthy person’s genome harbors about 100 genuine loss of function variants, 
most of which represent heterozygous variants in nonessential genes, with only 
about 20 variants inactivating a gene’s function entirely.41 
 
Given the large number of variants identified in WES and WGS, several methods 
can winnow down the number of variants to key candidate variants. Many 
studies, such as the first WES studies34,35 and the work presented herein, use 
filtering strategies based on hypotheses about the characteristics of causative 
variants expected. Larger studies, especially those without familial samples, have 
opted for statistical association tests, either designed for single variants or 
clusters of variants. 
 
As a first step in both filtering strategies and association analysis, sequencing 
studies typically apply annotation and in silico prediction programs. Through 
annotation software, researchers are able to assign putative function (e.g. 
location within or outside of an exon, name of the nearest gene, effect on the 
mRNA or protein sequence if any, variant frequencies, etc.) to variants. In silico 
prediction programs help researchers determine the impact of a particular 
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variant. Some in silico programs measure the level of evolutionary conservation 
at a locus (where a more conserved location might imply that the locus has an 
important biological function, as deleterious mutations undergo purifying 
selection). Others focus on the variant’s effect on the structure, enzymatic 
function, or other important characteristics of the protein. A third class combines 
both conservation and protein effect predictions, and some even compute and 
aggregate predictions from multiple other in silico programs. 
 
Statistical association tests that can be applied to sequencing data are being 
developed at a rapid pace. Most of the available programs allow for testing the 
association of a single variant with the trait of interest, but these tests are 
generally not well powered for rare variants due to their infrequent observation in 
the dataset. In order to increase their power, most rare variant association tests 
combine rare variants in some fashion. The most popular grouping of variants to 
date has been by gene, although one might feasibly also look at variants across 
a group of genes or a pathway. Two major types of these collapsing or 
aggregative association tests exist. One version tabulates the number of rare 
alleles in a gene for each sample and compares the general ‘burden’ of rare 
alleles in cases versus controls. The other type, termed as a variance-component 
test, allows for variants to have either deleterious or protective effects by 
comparing the number of variants with non-zero effect sizes to expected 
scenarios. Although these tests have not been employed in the work presented 
herein, future studies will undoubtedly use later generations of these programs. A 
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recent review by Lee and colleagues lists some of the specific programs and 
considerations for each category of test.42 
 
The bioinformatics programs used in the present work are listed in Table 2. 
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Table 2. Bioinformatics programs utilized. SNV = single nucleotide variant; 
indel = insertion/deletion 
Program 
category 
Program Name Description 
Alignment Burrows Wheeler Aligner 
(BWA)43 
Common aligner used for its 
general speed and accuracy 
Variant 
detection 
Genome Analysis Toolkit 
(GATK)44 
1. Unified Genotyper 
2. Haplotype Caller 
Common variant caller used mostly 
for SNVs and indels; also 
recalibrates alignments 
 SAMTools45 Common variant caller used mostly 
for SNVs and indels 
In silico 
prediction  
Combined Annotation 
Dependent Depletion (CADD)46 
Scores the relative deleteriousness 
of a variant based on a number of 
other in silico prediction programs 
 DDIG-in47 Predicts locus conservation for 
non-frameshifting indels 
 GERP48 Predicts locus conservation 
 MutPred49 Predicts locus conservation and 
variant impact on resultant protein 
 PolyPhen50 Predicts variant impact on resultant 
protein 
 Residual Variation Intolerance 
Score (RVIS)51 
Computes a relative score for how 
well a gene tolerates mutation 
 SIFT52 Predicts locus conservation for 
SNVs 
 SIFT-Indel53 Predicts locus conservation for 
frameshifting indels 
Other Picard 
(http://picard.sourceforge.net/) 
Used in this work for removal of 
duplicate reads 
 ANNOVAR54 Provides comprehensive 
annotation features 
 Integrated Genomics Viewer 
(IGV)55 
Manual inspection of read 
alignments and variant calls 
 Merlin56 Performs rapid linkage analysis 
17 
 
Sequencing applied to families 
Family-based studies have formed the foundation for WES and WGS 
approaches. Many initial studies focused on rare Mendelian diseases in families 
where initial linkage analysis had yielded a promising genetic interval, but a 
specific gene had not been identified. Instead of using the laborious Sanger 
sequencing method to examine all the large number of genes in these intervals, 
researchers could now utilize WES or WGS to quickly identify the causative 
mutation in the linkage families.57-61 Other studies applied WES or WGS to 
pedigrees that were uninformative for linkage because there were too few 
affected members or meioses, such as the Miller Syndrome case35 and the more 
recent studies of de novo germline mutations using trios.62-64 The typical workflow 
for a family-based sequencing study is depicted in Figure 3. 
 
Figure 3. Schematic workflow of family-based sequencing studies. 
Sequence members of a family 
Alignment, variant calling, variant annotation 
Assess for variant segregation with hypothesized mode of inheritance 
Retain variants of interest (e.g. rare, exonic, functional, predicted damaging) 
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More recently, WES and WGS have been applied to more common and complex 
diseases. Some multi-institutional collaborations have leveraged large cohorts of 
unrelated individuals, leading to discoveries of rare genetic risk factors involved 
in diabetes,65 cardiovascular phenotypes,66 and other traits. Other groups have 
continued using families to explore complex traits, either by including only 
unrelated familial samples or by sequencing multiple members of families per 
study. Some of the techniques developed in family-based sequencing studies, 
such as incorporating identity-by-descent (IBD) into quality control processes,67 
have also aided in the application of HTS to sporadic disease as well. 
 
Challenges in sequencing studies 
Despite the early successes of sequencing applied to familial disease and the 
resulting number of research groups focused in this area, a number of challenges 
remain in the field. Some of the ‘rate limiters,’ as described by Shendure et al, 
include the cost and effort of acquiring and storing samples, constructing 
libraries, sustaining technological infrastructure, and maintaining labor and 
expertise.33 General computational and bioinformatics challenges and potential 
solutions are also discussed by Berger and colleagues.68 
 
The interpretation of results from sequencing studies offers another multifaceted 
challenge. Variants of unknown significance (VUS), or variants whose 
biochemical and/or clinical significance has not been identified or confirmed, 
often are the sole products of sequencing experiments. In silico prediction 
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programs can highlight particular variants of interest or provide ideas on how to 
molecularly characterize the variants identified, but they serve only as the first 
step in understanding the functional impact of a variant on disease. Bell and 
colleagues, for instance, showed that 27% of 406 published sequencing variants 
indicated as severe disease mutations actually were common SNPs or did not 
have enough evidence to confirm pathogenicity.69 Others have urged caution in 
assigning pathogenicity to variants before rigorous follow-up in order to avoid 
adverse consequences for patients and research.70 In addition to the confusion 
and discrepancies in nomenclature for the relatively new field of sequencing, the 
field lacks a gold standard for following-up VUS. Depending on the nature of 
each VUS and the disease of interest, different follow-up studies may include 
additional population genetic study designs, expression studies, molecular 
characterization of a gene or pathway, or more. Such studies can take anywhere 
from a few years to decades. Thus, there is a delicate balance between 
accumulating and publishing results from sequencing and biochemical analyses 
in order to advance research findings and ultimately serve pressing clinical 
needs. 
 
Furthermore, despite the incredible potential of WES and WGS, these 
technologies are still limited. WES only captures about 1% of the genome, and 
captures vary in their target intervals and weaknesses.71 WGS, although it covers 
the entire genome by definition, may not have enough sequencing depth in some 
regions to accurately call variants. Additionally, the relative costs of WES versus 
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WGS may make it more cost effective to choose WES and sequence a larger 
number of individuals. For either technology, certain regions of the genome like 
highly repetitive sequence and CG-rich intervals are still difficult to sequence 
accurately.72 For the variants that can be detected by WES or WGS, different 
analysis methods must be used to look for different types of variants present. 
Different bioinformatics programs, spanning the alignment step to variant calling, 
are more sensitive or specific to different types of variation. While some variant 
calling programs that call SNVs have been extensively tested, programs 
targeting indels, copy number variations (CNV), and other types of variants are 
currently less sophisticated (types of variants that can be identified through 
sequencing are depicted in Figure 4). For variants identified by these 
approaches, more extensive confirmation steps are necessary. Additionally, even 
for SNVs, important discrepancies still exist between variant callers. For 
instance, O’Rawe et al found only a 57.4% concordance across 5 SNV variant 
calling pipelines used on 15 exomes.73 
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Figure 4. Types of variants that can be identified through high-throughput 
sequencing. Each letter (A, B, C, D) corresponds to a distinct gene. Single 
nucleotide variants (SNVs) are <5% minor allele frequency (MAF), whereas 
single nucleotide polymorphisms (SNPs) are >5% MAF. Sequence variation 
refers to SNV/SNPs or small (<1kb) indels. Rahim et al, 2008.74 
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Researchers rely on accurate annotation of variants to narrow down groups of 
variants to study further. While there are some common sources for these 
annotations, there are still discrepancies between even commonly used 
databases.75 Bioinformatics programs that facilitate annotation of sequencing 
data may also resolve discrepancies in slightly different ways,39 adding more 
difficulty in attempts to combine or replicate results. Additionally, the number and 
types of in silico prediction programs have exploded in the past few years. 
Sensitivities and specificities of each program differ from one another,76-79 and 
there is still not a gold standard approach to their application. 
 
As sequencing is applied to more complex diseases, questions about study 
design, including the number and type of samples to include as well as the 
appropriate statistical tests to employ, become more intricate.80 In order to 
expand sample sizes, some research groups have combined sequencing data 
from other groups and/or data repositories. Batch effects, or variation due to 
varying experimental conditions (e.g. temperature, time, personnel), can be 
widespread in such situations.81,82 Furthermore, the possible introduction of false 
signals from minor differences in ancestry is likely to be more misleading in 
analysis of rare sequencing variants as opposed to GWA studies.39 Researchers 
are actively working on identifying and correcting for such quality control errors to 
increase reproducibility. 
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To add another complicating factor, allelic architecture, or the numbers and types 
of risk variants, is known to differ substantially between diseases.23,83 Manolio 
and colleagues, for instance, cite how the majority of heritability for age-related 
macular degeneration can be explained by 5 loci, whereas several dozen loci of 
smaller effect size have been identified for Crohn’s disease.23 Unlike previous 
linkage and GWA studies, sequencing has the potential of identifying variants 
across the spectrum of frequencies and effect sizes, but different types of 
analyses may need to be performed to determine robust associations. 
 
Statement of Purpose 
In the present study, WES and WGS are applied to familial cases of 3 different 
disease models: intracranial aneurysm (IA), Parkinson disease (PD), and X-
linked ataxia dementia (XLAD). Through these examples of familial disease, we 
explore the opportunities and challenges of family-based HTS. The work 
presented herein contributes effective practices for study design, analysis, and 
interpretation in a rapidly growing field still replete with questions about how best 
to implement HTS in studying familial disease. 
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CHAPTER I: FAMILIAL INTRACRANIAL ANEURYSM 
 
Introduction 
Subarachnoid hemorrhage (SAH) is the most devastating subtype of stroke. 
Fatality from SAH between 21 days to one month of the hemorrhage ranges from 
25-35% in high-income countries to almost 50% in low- to middle-income 
countries.84 Up to 80-90% of SAH cases are caused by rupture of IA, which are 
present in approximately 3% of the population.85 Smoking and hypertension are 
important risk factors, increasing the risk of IA rupture by 3.1 and 2.6 times 
respectively.86 The risk of an IA and for IA rupture is also increased among 
individuals having a first-degree relative with a history of an IA 85,87,88. The 
location and number of IAs in a given individual also appears to be influenced by 
a family history.89 Thus, several lines of evidence suggest that IA is due to both 
genetic and environmental risk factors. Unfortunately, until more is understood 
about these risk factors, the severe morbidity and mortality associated with this 
disease will continue to be a large public health burden. 
 
Several approaches have been employed to identify genes contributing to IA. 
Initial studies utilized pedigrees having multiple affected members. Analyses in 
these initial studies detected linkage to several chromosomal regions (1p34.3-
36.1390,91, 4q32.292, 6p2393,7q1190, 7q36.392, 8q12.192, 11q24-2593-95, 
12q21.3392, and 14q23-3195); however, the causative gene was not identified in 
any of these regions. More recently, GWA studies have focused on the role of 
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common variants that might individually have a small effect on disease risk. 
Analyses have consistently detected association to SNPs in CDKN2BAS, also 
known as ANRIL, on chromosome 9p21.396-98, as well as SOX17 on 
chromosome 8q12.196-98. Association has also been reported to EDNRA on 
chromosome 4q3199, CNNM2 on chromosome 10q2497, KL/STARD13 on 
chromosome 13q1397, and RBBP8 on chromosome 18q1197. Together, these 
genes only explain a fraction of the population attributable risk for IA. 
 
Advances in technology, especially in the development of HTS, now make it 
possible to efficiently search for rare variants having a large effect on disease 
risk. These rare variants may point to novel genes and pathways that are critical 
to improve the molecular understanding of IA and methods of predicting those at 
greatest risk. In the present work, WES was applied to a unique set of families 
densely affected with IA to investigate the role of rare genetic variation in disease 
susceptibility and to demonstrate important study design considerations for WES 
studies in complex disease. 
 
Materials and methods 
Families selected for whole exome sequencing 
Individuals were recruited as part of the Familial Intracranial Aneurysm (FIA) 
Study.100 Study approval was granted by the institutional review boards at 
Indiana University, University of Cincinnati, and all participating study sites. 
Written consent was obtained from all study participants. 
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Families were recruited to ensure that DNA could be obtained from at least two 
living affected relatives and that the family would be informative for linkage 
analysis. Exclusion criteria included (i) a fusiform-shaped unruptured IA of a 
major intracranial trunk artery; (ii) an IA that is part of an arteriovenous 
malformation; (iii) a family or personal history of polycystic kidney disease, Ehlers 
Danlos syndrome, Marfan’s syndrome, fibromuscular dysplasia, or Moya-Moya 
disease; or (iv) failure to obtain informed consent from the patient or family 
members. To identify unruptured IA, magnetic resonance angiography (MRA) 
was offered to first degree relatives of affected family members who had a higher 
risk of IA as defined by: 1) 30 years of age or older and 2) either a 10 pack year 
history of smoking or an average blood pressure of ≥140 mmHg systolic or ≥90 
mmHg diastolic. 
 
Only individuals having an IA based on an intra-arterial angiogram, operative 
report, autopsy, or size ≥7 mm on non-invasive imaging (MRA) were considered 
“definite” cases (Table 3). Two neurologists independently reviewed each record 
to determine if a subject met all inclusion and exclusion criteria. In case of 
disagreement, a third neurologist reviewed the data.  
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Table 3. Intracranial aneurysm disease phenotypes. Classification of affected 
status of samples in the Familial Intracranial Aneurysm Study. 
Classification Definition 
Definite Medical records document an intracranial aneurysm (IA) on 
angiogram, operative report, autopsy, or a non-invasive 
imaging report (MRA, CTA) demonstrates an IA measuring 
7mm or greater. 
Probable Death certificate mentions probable IA without supporting 
documentation or autopsy. Death certificate mentions 
subarachnoid hemorrhage (SAH) without mention of IA and a 
phone screen is consistent with ruptured IA (severe headache 
or altered level of consciousness) rapidly leading to death. An 
MRA documents an IA that is less than 7 mm but greater than 
3 mm. 
Possible Non-invasive imaging report documents an aneurysm 
measuring between 2 and 3 mm or SAH was noted on death 
certificate, without any supporting documentation, autopsy or 
recording of headache or altered level of consciousness on 
phone screen. Death certificate lists ‘aneurysm’ without 
specifying cerebral location or accompanying SAH. 
Not a case There is no supporting information for a possible IA. 
 
 
28 
 
 
Seven families of European American descent with the highest density of 
affected individuals who also had DNA available were selected for WES101 
(Figure 5). All affected individuals for which sufficient DNA was available were 
selected for sequencing. Unaffected individuals were selected only if there was 
an MRA conducted that confirmed the absence of an IA at 45 years or older and 
if there was sufficient DNA available. One clinically unaffected individual in family 
E was assumed to be an obligate carrier and was sequenced with her offspring 
to allow confirmation of allele transmission. Within the seven families, 45 
individuals were chosen for WES. 
 
Figure 5. Simplified pedigrees for the intracranial aneurysm whole exome 
sequencing families. Only sequenced individuals and those needed to preserve 
generational structure are shown to protect the anonymity of the pedigree. 
IA=intracranial aneurysm. All affected individuals are definite IA unless noted as 
a probable IA, possible IA, or aortic abdominal aneurysm (AAA). Criteria for 
defining definite, probable, and possible IA statuses are outlined in Table 1. All 
unaffected individuals, with the exception of individual E-9, had an MRA 
performed that did not show evidence of an IA. Grey indicates an unknown 
phenotype. An ‘S’ above an individual denotes that the individual was selected 
for sequencing. 
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Whole exome sequencing 
WES was performed at the Center for Inherited Disease Research (CIDR, Johns 
Hopkins University). Exonic sequences were captured using the Agilent 
SureSelect Human All Exon 50Mb kit, and paired-end sequencing was performed 
on the Illumina HiSeq 2000 system, using Flowcell version 3 and TruSeq Cluster 
Kit version 3. All samples were genotyped using the Illumina 
HumanOmniExpress-12v1_C platform for quality assurance. Two HapMap 
samples and two study duplicates were used to ensure library preparation batch 
quality. 
 
Whole exome sequencing bioinformatics 
Primary analysis was done using HiSeq Controls Software and Runtime Analysis 
Software. The CIDRSeqSuite pipeline was used for secondary bioinformatics 
analysis, which consists mainly of alignment using BWA (version 0.5.9)43 to the 
human genome reference sequence (build hg19) and applying GATK (version 
1.0.4705)44 to perform local realignment and base quality score recalibration. 
Duplicate molecules were flagged and mate-pair information synchronized using 
Picard (version 1.52, http://picard.sourceforge.net/). The GATK Unified 
Genotyper (GATK version 1.2-29) was used for multi-sample variant calling. The 
dataset, consisting of called variants, subject phenotypes, and pedigree 
information for the multiplex IA families can be requested directly from the 
National Center for Biotechnology Information (NCBI) Database of Genotypes 
and Phenotypes (dbGaP) (accession phs000636). Mapped reads are available 
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on the Sequence Read Archive (http://www.ncbi.nlm.nih.gov/sra) (accession 
SRX329208-SRX329252). 
 
GATK VQSR (GATK version 1.2-38)102 created a high-quality call set for SNVs 
by using an adaptive error model to estimate the likelihood of true genotype calls 
based on aggregating information across multiple quality metrics. As 
recommended by GATK, HapMap 3.3 and the Illumina Omni 2.5M chip sites, 
available from the GATK bundle 1.2, were used as training sets and the 
annotations of Quality by Depth, Haplotype Score, Mapping Quality Rank Sum, 
Read Position Rank Sum, Fisher Strand Bias Test, and Mapping Quality were 
used as quality metrics for the recalibration. SNVs were filtered until 99% of the 
overlapping HapMap 3.3 sites were retained after application of VQSR. 
Insertion/deletions were removed if they had a quality by depth < 2.0, 
ReadPosRankSum < -20.0 (Z-score from Wilcoxon rank sum test of alternative 
versus reference read position bias), Fisher’s Strand Bias > 200.0 (phred-scaled 
p-value using Fisher’s exact test to detect strand bias), and/or a homopolymer 
run > 5. 
 
ANNOVAR54 was used to annotate variants for location, predicted effect on the 
protein across three gene databases (RefSeq, UCSC, and Ensembl), and 
corresponding gene and transcript length. Allele frequencies within European 
American populations in 1000 Genomes (February 2012 release, 
http://www.1000genomes.org)36 and the Exome Sequencing Project (ESP) 
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(ESP6500 release with insertion/deletions and chromosome X and Y calls, 
http://evs.gs.washington.edu/EVS/)103 were recorded using custom scripts. The 
scripts mapped variants to 1000 Genomes and ESP based on chromosomal 
position and reference and alternate alleles to determine allele frequencies. If a 
variant was not found in 1000 Genomes or ESP, the alternate allele frequency 
was set to 0. If a variant was found in both 1000 Genomes and ESP, the smaller 
alternate allele frequency was taken as the consensus frequency. 
 
Variants were annotated for binned minor allele frequencies from 290 samples 
without a known cardiovascular phenotype that were exome sequenced at CIDR 
using identical capturing  and sequencing technology, although SAMtools45 was 
used for variant calling instead of GATK Unified Genotyper. Variants that were 
monomorphic across all samples were also flagged. 
 
Variants were also annotated using custom scripts for Gene Ontology (GO) 
(http://www.geneontology.org)104 terms that were hypothesized to play a role in 
IA pathophysiology. GO terms used included GO:0001944 (vasculature 
development), GO:0001570 (vasculogenesis), GO:0003018 (vascular process in 
circulatory system), GO:0005581 (collagen), GO:0005604 (basement 
membrane), and GO:0051541 (elastin metabolic process). 
 
Two programs were used to predict the pathogenicity of SNVs: SIFT52 and 
PolyPhen-2105. Scores of damaging for SIFT, or possibly or probably damaging 
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for PolyPhen-2, were accepted as evidence for pathogenicity. Two additional 
programs were used to analyze the effect of insertions and deletions: SIFT-
INDEL53 for those that cause a frameshift, and DDIG-in for those that do not 
cause a frameshift47. Variants were also annotated for C-scores from the 
Combined Annotation Dependent Depletion (CADD) webserver 
(http://cadd.gs.washington.edu)46. C-scores of 10 or greater, corresponding to 
the 10% most deleterious substitutions in the human genome according to 
CADD, were considered damaging predictions. 
 
Biological filtering retained loci if they: 1) were autosomal variants; 2) were 
predicted to be nonsynonymous SNVs or insertion/deletions in an exonic and/or 
splicing region (within 2 bp of a splicing junction, as annotated by ANNOVAR) 
based on RefSeq, UCSC, and Ensembl annotations; 3) had an allele frequency 
in European American populations <1% (1000 Genomes, ESP); 4) had an allele 
frequency less than 1% in CIDR binned minor allele frequencies and were not 
monomorphic across all samples; 5) were predicted most likely to be damaging 
by CADD and by at least one other protein prediction program; and 6) 
segregated with all individuals with a definite IA and obligate carriers in at least 
one family. All alignments for variants passing these biological filters were 
visually inspected using the Integrated Genomics Viewer (IGV)55 to confirm 
presence of a variant. Visual inspection for each variant included reviewing read 
pair orientations, mappability, and soft-clipping; variants that were called nearby; 
overall depth of sequencing and genomic features that might have inhibited 
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coverage at that locus; and repetitive sequence that might have influenced the 
position or variant allele called for the locus.  In addition to the filters described 
above, insertion/deletions were also compared against a different dataset 
consisting of approximately 500 samples without a known cardiovascular 
phenotype. This comparison dataset used GATK Unified Genotyper (version 2.3-
9) for variant calling and the Agilent SureSelect Human All Exon 51Mb capture 
kit. If the allele designations and/or positions did not match between the two 
datasets but were within 10 bp, manual review of both the IA and comparison 
BAM files with IGV was done to reconcile differences in allele designations and 
position assignments between the two datasets. 
 
Loci were also annotated if they: A) segregated with all aneurysms (including 
probable and possible IA and the one abdominal aortic aneurysm case in family 
G) and B) were not found in any sequenced unaffected individuals, excluding 
assumed obligate carriers. 
 
Linkage 
The 7 families were included as part of a larger linkage study of 2,317 individuals 
from 394 families using the 6K Illumina array.92 Multipoint parametric linkage 
analysis (autosomal dominant inheritance, 1% disease allele frequency was 
performed using Merlin.56 Only genotypic data from family members with definite 
IA and obligate carriers were included in the linkage analysis. WES variants were 
annotated for the highest LOD score obtained by linkage markers within a 10Mb 
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window centered on the sequencing variant. A maximum possible LOD score for 
each family was calculated by simulating a hypothetical fully informative marker 
using the aforementioned model parameters and the pedigrees for each family. 
 
Tissue collection for RNA expression 
Aneurysm biopsies from the aneurysm fundus distal to the clip were collected 
from patients undergoing neurosurgical clipping of an IA at the Department of 
Neurology and Neurosurgery in the University Medical Center Utrecht in the 
Netherlands. These patients were completely independent of the families 
included for WES. Patients undergoing surgery because of intractable epilepsy 
were included as controls, and part of a superficial cortical artery in the resected 
part of the brain was excised as control vessel tissue. Samples were collected 
from 44 aneurysm biopsies (22 ruptured, 21 unruptured, 1 with unknown rupture 
status) and 16 control biopsies. All samples were immediately snap frozen in 
liquid nitrogen less than 1 minute after excision and stored at -80 °C until further 
use. 
 
RNA isolation, sample preparation, and sequencing 
RNA isolation, sample preparation, and sequencing was conducted at the 
University Medical Center Groningen in Groningen, the Netherlands. Each 
sample was homogenized with zirconia/silica beads in the BeadBeater machine 
(BioSpec products, Inc.). After homogenization, total RNA was extracted and 
purified using an RNeasy microkit (Qiagen, Valencia, CA, USA) according to the 
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manufacturer’s instructions. An initial quality check of the samples by capillary 
electrophoresis and RNA quantification for each sample was performed using the 
LabChip GX (PerkinElmer, Waltham, Massachusetts, USA). Samples with a 
minimum amount of 7 ng non-degraded RNA were selected for subsequent 
sequencing analysis. Sequence libraries were generated using the TruSeq RNA 
sample preparation kit from Illumina (San Diego, USA) using the Sciclone NGS 
Liquid Handler (Perkin Elmer). To remove contamination of adapter-duplexes, an 
extra purification of the libraries was performed with the automated agarose gel 
separation system Labchip XT (Perkin Elmer). The obtained cDNA fragment 
libraries were sequenced on an Illumina HiSeq2000 using default parameters 
(single read 1x100bp) in pools of 10 or 11 samples. Processing of the raw data, 
including a demultiplexing step, was performed using Casava software (Illumina) 
with standard settings. 
 
Differential expression analysis 
Sequencing reads with quality score under Phred Score <30 were discarded. The 
quality filtered trimmed fastQ files were then aligned to the human reference 
genome (hg19) using the STAR aligner,106 allowing for 2 mismatches. SAMtools 
version 0.1.1845 was used to sort the aligned reads. Gene level quantification 
was performed by HTSeq-0.5.4107 using parameters --mode=union --
stranded=no and Ensembl version 71 as the gene annotation database. 
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R version 3.1.0 was used for differential expression analysis. The counts per 
gene for each sample obtained after alignment were used as input for the 
analysis. Low count genes (genes with less than 1 read per million in n of the 
samples, where n is the size of the smallest group of replicates, i.e. n=16) were 
filtered out since there is little power to detect significant evidence of differential 
expression in these genes.108 
 
The Bioconductor (version 2.14) packages edgeR (version 3.6.2) and limma 
(version 3.20.2) were used for subsequent steps. To correct for technical 
influences, edgeR adjusts for varying sequencing depths between samples and 
normalizes for the RNA composition of the sample. A generalized linear model 
was used to test for differential expression between aneurysmal and control 
tissue. Other factors included in the model were age and sex of patients, as well 
as rupture status. Common and tagwise dispersion estimates were calculated 
with the Cox-Reid profile adjusted likelihood method to be able to correct for the 
technical and biological variation when fitting the multivariate negative binomial 
model. In estimating the tagwise dispersion, the program default for degrees of 
freedom (df=10) was used. A negative binomial generalized log-linear model, 
using the tagwise dispersion estimates, was fitted to the read counts for each 
gene, and a gene-wise statistical test was performed. Then, a likelihood ratio test 
was performed. Benjamini Hochberg false discovery rates (FDR) for a 
transcriptome-wide experiment were calculated to correct for multiple testing. All 
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genes with an FDR adjusted p-value <0.05 were considered individual genes of 
interest. 
 
Results 
Sequencing data quality 
The average study duplicate reproducibility of SNV and insertion/deletion calls 
were 99.13% and 94.42%, respectively, and genotypes for non-reference calls 
per sample from the WES data achieved an average 99.57% concordance with 
genotype calls from the Illumina® HumanOmniExpress-12v1_C array. The 
average sensitivity to heterozygote calls on the array was 98.13%. After 
application of GATK quality filters, 98,351 SNVs and 5,851 insertion/deletions 
were retained. The transition-transversion ratio for exonic variants and percent of 
SNVs in dbSNP 137, both measures of the quality of the data, were 3.3 and 
94.79% respectively. 
 
Biological Filtering 
The number of variants retained after each biological filter employed in the 
Methods is shown in Tables 4-5 for SNVs and insertion/deletions, respectively. 
The list of SNVs and insertion/deletions satisfying biological filters 1-6 is shown in 
Table 6. The final candidate variants passing biological filters 1-6 and manual 
inspection include 67 SNVs and 1 deletion. The sets of variants that A) segregate 
with all aneurysmal phenotypes and B) are not carried in unaffected individuals 
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are included in Table 6 as subsets of the 68 final variants. The limitations of only 
considering these sets of variants are described in the Discussion. 
  
 
 
Table 4. Intracranial aneurysm whole exome sequencing single nucleotide variant filtering pipeline. 
Numbers in parentheses refer to filtering steps described in the Methods. IA = intracranial aneurysm 
Family A B C D E F G All 
All variants found in at least one definite IA 46168 41978 44689 44515 49142 39495 37809 98351 
(1) Autosomal variants 45390 41280 43994 43701 48376 38925 37251 96552 
(2) Variants predicted to be functional 12261 11158 11849 11841 13203 10578 10025 29194 
(3) Rare variants 1020 889 953 1298 1356 843 823 7845 
(4) Variants not found or of low frequency 
in the internal allele frequency database 793 725 740 1028 1049 676 658 6428 
(5) Variants predicted damaging 393 345 369 442 470 297 306 3008 
(6) Variants segregating with all definite IA 
in at least one family 13 11 2 10 4 8 24 67 
Variants passing visual inspection 13 11 2 10 4 8 24 67 
A. Variants segregating with all IA 
(definite, probable, possible) or AAA in at 
least one family 13 9 2 8 3 8 7 46 
B. Variants not found in unaffected 
individuals 5 2 1 7 3 1 0 19 
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Table 5. Intracranial aneurysm whole exome sequencing insertion deletion filtering pipeline. Numbers in 
parentheses refer to filtering steps described in the Methods. IA = intracranial aneurysm 
Family A B C D E F G All 
All variants found in at least one definite IA 3316 2736 3226 3166 3396 2987 2966 5851 
(1) Autosomal variants 3264 2705 3178 3102 3345 2940 2921 5737 
(2) Variants predicted to be functional  538 457 560 541 581 511 465 1126 
(3) Rare variants 284 221 299 277 299 266 260 589 
(4) Variants not found or of low frequency 
in the internal allele frequency database 178 159 188 171 192 165 157 453 
(5) Variants predicted damaging 60 59 65 50 59 55 42 194 
(6) Variants segregating with all definite IA 
in at least one family 24 22 23 19 23 24 19 26 
Variants passing visual inspection and 
manual review with internal database calls 0 0 0 0 0 0 1 1 
A. Variants segregating with all IA (definite, 
probable, possible) or AAA in at least one 
family 0 0 0 0 0 0 0 0 
B. Variants not found in unaffected 
individuals 0 0 0 0 0 0 0 0 
41 
 
 
Table 6. Candidate variants identified through whole exome sequencing in the intracranial aneurysm whole 
exome sequencing families. Chr = chromosome, Pos = position, Ref = reference allele, Alt = alternate allele. Alt 
Freq = alternate allele frequency (consensus frequency for the alternate allele from 1000 Genomes and/or Exome 
Sequencing Project, as described in the Methods), LOD = maximum LOD score for linkage markers found within a 
10Mb window of the sequencing variant, Fam = family, Unaff = number of sequenced unaffected individuals who 
carry the variant, logFC = log fold change of expression differential (N/A indicates no expression data is available 
for the gene), FDR = false discovery rate-adjusted p-value. All variants are predicted to be non-synonymous exonic 
variants except the deletion at the end of the Table. A plus sign (+) denotes a damaging prediction. For variants 
segregating in families B, D, or G, a (§) indicates that variant was also shared by an individual in the same family 
with a probable or possible IA or an abdominal aortic aneurysm.  
Chr Pos Ref Alt Gene Full_Name 
Alt 
Freq 
Protein Prediction 
Programs 
Amino Acid 
Change LOD Fam Unaff 
logF
C FDR 
Poly 
Phen SIFT 
CADD 
1 6631
121 
C T TAS1
R1 
taste 
receptor, 
type 1, 
member 1 
0.0001   + 16.77 
NM_17754
0:exon2:c.
C344T:p.T
115M 
1.08 
D§ 0 N/A N/A 
1 1590
5363 
G T AGMA
T 
agmatine 
ureohydrol
ase 
0.0026   + 15.62 
NM_02475
8:exon4:c.
C711A:p.N
0.83 
F 1 -
0.127 
0.952 
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(agmatinas
e) 
237K 
1 2820
6319 
G A C1orf
38 
chromoso
me 1 open 
reading 
frame 38 
0.0001 + + 17.71 
NM_00110
5556:exon
3:c.G400A:
p.A134T 
0.57 
G§ 0 N/A N/A 
1 2847
7192 
T C PTAF
R 
platelet-
activating 
factor 
receptor 
0.0052 + + 20.80 
NM_00116
4721:exon
3:c.A341G:
p.N114S 
0.57 
G§ 0 -
0.506 
0.867 
1 3376
0820 
G A ZNF3
62 
zinc finger 
protein 362 0.0000 +   21.80 
NM_15249
3:exon8:c.
G1060A:p.
A354 
0.85 
B§ 1 0.336 0.784 
1 3663
8206 
G A MAP7
D1 
MAP7 
domain 
containing 
1 
0.0011 + + 34.00 
NM_01806
7:exon4:c.
G602A:p.R
201Q 
0.47 
D§ 0 0.157 0.792 
1 1119
6801
1 
G A OVGP
1 
oviductal 
glycoprotei
n 1, 
120kDa 
0.0000 + + 12.85 
NM_00255
7:exon4:c.
C311T:p.T
104I 
0.57 
G§ 1 -
0.023 
0.988 
1 1778
9968
9 
C A SEC1
6B 
SEC16 
homolog B 
(S. 
cerevisiae) 
0.0010 + + 21.60 
NM_03312
7:exon25:c.
G3102T:p.
Q1034H 
0.87 
C 0 N/A N/A 
1 1970
7243
4 
T A ASPM asp 
(abnormal 
spindle) 
homolog, 
microcepha
ly 
0.0013 +   14.55 
NM_01813
6:exon18:c.
A5947T:p.
M1983L 0.57 
G§ 1 1.195 0.642 
43 
 
 
associated 
(Drosophila
) 
1 2044
1841
1 
C T PIK3C
2B 
phosphoino
sitide-3-
kinase, 
class 2, 
beta 
polypeptide 
0.0007 + + 35.00 
NM_00264
6:exon15:c.
G2248A:p.
G750S 
0.57 
G§ 1 -
0.505 
0.672 
1 2127
9929
0 
C A FAM7
1A 
family with 
sequence 
similarity 
71, 
member A 
0.0000 +   13.78 
NM_15360
6:exon1:c.
C1071A:p.
S357R 
0.57 
G§ 1 N/A N/A 
1 2282
9005
1 
T G C1orf
35 
chromoso
me 1 open 
reading 
frame 35 
0.0093 +   21.10 
NM_02431
9:exon5:c.
A407C:p.E
136A 
-
0.29 
A 0 -
0.079 
0.934 
2 1018
6509 
C T KLF11 Kruppel-
like factor 
11 0.0003 
+ + 14.69 
NM_00117
7718:exon
2:c.C224T:
p.P75L 
1.41 
A 0 -
0.129 
0.892 
2 5582
5844 
A G SMEK
2 
SMEK 
homolog 2, 
suppressor 
of mek1 
(Dictyosteli
um) 
0.0026 + + 23.90 
NM_00112
2964:exon
4:c.T629C:
p.F210S 1.43 
E 0 -
0.222 
0.631 
2 7371
8061 
A G ALMS
1 
Alstrom 
syndrome 
1 0.0000 
+ + 12.02 
NM_01512
0:exon10:c.
A8972G:p.
D2991G 
1.13 
D§ 0 -
0.264 
0.749 
44 
 
 
2 7475
7348 
T C HTRA
2 
HtrA serine 
peptidase 2 0.0030 + + 11.98 
NM_01324
7:exon1:c.
T215C:p.L
72P 
1.43 
E 0 0.267 0.595 
2 1610
2915
7 
G C ITGB6 integrin, 
beta 6 0.0001 + + 17.45 
NM_00088
8:exon6:c.
C844G:p.L
282V 
-
0.84 
G 1 N/A N/A 
3 1261
3755
6 
G A CCDC
37 
coiled-coil 
domain 
containing 
37 
0.0052 +   12.36 
NM_18262
8:exon7:c.
G589A:p.A
197T 
-
0.84 
G 2 N/A N/A 
3 1803
3445
8 
C T CCDC
39 
coiled-coil 
domain 
containing 
39 
0.0026 +   20.70 
NM_18142
6:exon18:c.
G2432A:p.
R811H 
0.22 
A 1 0.167 0.882 
3 1865
0802
4 
A C RFC4 replication 
factor C 
(activator 
1) 4, 37kDa 
0.0000   + 12.98 
NM_00291
6:exon10:c.
T903G:p.H
301Q 
0.83 
F 1 0.125 0.906 
4 1061
5813
4 
C T TET2 tet 
oncogene 
family 
member 2 
0.0000 + + 12.41 
NM_01762
8:exon3:c.
C3035T:p.
P1012L 
0.57 
G§ 1 -
0.231 
0.878 
*4 1066
3917
6 
T A GSTC
D 
glutathione 
S-
transferase
, C-terminal 
domain 
containing 
0.0047 +   22.90 
NM_00103
1720:exon
2:c.T406A:
p.C136S 
0.57 
G§ 1 -
0.199 
0.781 
5 1101
8087 
T C CTNN
D2 
catenin 
(cadherin-
0.0000 +   25.80 NM_00133
2:exon18:c.
-
0.29 
A 0 -
1.940 
0.401 
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associated 
protein), 
delta 2 
(neural 
plakophilin-
related 
arm-repeat 
protein) 
A3083G:p.
K1028R 
5 1408
0189
7 
C T PCDH
GA11 
protocadhe
rin gamma 
subfamily 
A, 11 
0.0007   + 18.54 
NM_01891
4:exon1:c.
C1103T:p.
A368V 
0.57 
G 1 -
0.587 
0.624 
5 1409
5583
5 
C T DIAP
H1 
diaphanous 
homolog 1 
(Drosophila
) 
0.0007 +   36.00 
NM_00521
9:exon14:c.
G1423A:p.
E475K 
0.57 
G 1 0.344 0.612 
5 1499
0105
5 
G A NDST
1 
N-
deacetylas
e/N-
sulfotransfe
rase 
(heparan 
glucosamin
yl) 1 
0.0036 +   18.54 
NM_00154
3:exon2:c.
G239A:p.R
80H 
1.43 
E 0 -
0.157 
0.806 
5 1570
5361
0 
T C SOX3
0 
SRY (sex 
determinin
g region 
Y)-box 30 
0.0013 +   15.84 
NM_17842
4:exon5:c.
A2000G:p.
N667S 
0.83 
F 0 N/A N/A 
6 1331
6909 
G T TBC1
D7 
TBC1 
domain 
family, 
member 7 
0.0042 + + 23.60 
NM_00114
3965:exon
5:c.C413A:
p.A138D 
0.86 
G§ 1 -
0.372 
0.758 
46 
 
 
6 1498
5680
2 
C T PPIL4 peptidylprol
yl 
isomerase 
(cyclophilin
)-like 4 
0.0000 + + 34.00 
NM_13912
6:exon5:c.
G394A:p.G
132S 
-
0.29 
A 0 0.100 0.900 
6 
1594
2063
0 A T 
RSPH
3 
radial 
spoke 3 
homolog 
(Chlamydo
monas) 
0.0002 + + 15.37 
NM_03192
4:exon1:c.
T379A:p.C
127S 
0.57 
G 1 
-
0.140 
0.858 
6 
1677
0970
5 G A 
UNC9
3A 
unc-93 
homolog A 
(C. 
elegans) 
0.0052 +   24.10 
NM_00114
3947:exon
3:c.G455A:
p.G152D 
0.85 
B 1 
N/A N/A 
6 
1683
1779
4 A C 
MLLT
4 
myeloid/ly
mphoid or 
mixed-
lineage 
leukemia 
(trithorax 
homolog, 
Drosophila)
; 
translocate
d to, 4 
0.0000 + + 26.90 
NM_00120
7008:exon
18:c.A2522
C:p.K841T 
0.57 
G§ 1 
-
0.150 
0.884 
8 
7295
8750 T A 
TRPA
1 
transient 
receptor 
potential 
cation 
channel, 
subfamily 
A, member 
0.0000 +   14.64 NM_00733
2:exon17:c.
A2059T:p.
N687Y 
-
0.96 
G 0 
N/A N/A 
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1 
9 
2116
6077 T C 
IFNA2
1 
interferon, 
alpha 21 
0.0002   + 10.42 
NM_00217
5:exon1:c.
A535G:p.K
179E 
1.12 
D§ 0 
N/A N/A 
9 
3540
4008 G A 
UNC1
3B 
unc-13 
homolog B 
(C. 
elegans) 
0.0006 + + 34.00 
NM_00637
7:exon39:c.
G4754A:p.
R1585H 
0.83 
F 1 
-
0.377 
0.658 
10 
1324
0791 C A 
MCM1
0 
minichromo
some 
maintenanc
e complex 
component 
10 
0.0049 +   17.17 NM_018518:exon16:c.
C2222A:p.
T741K 
0.85 
B 1 
1.318 0.563 
10 
4708
7309 G C 
PPYR
1 
pancreatic 
polypeptide 
receptor 1 
0.0000 + + 15.45 
NM_00597
2:exon3:c.
G526C:p.A
176P 
0.57 
G§ 1 
N/A N/A 
10 
8218
7167 G A 
C10or
f58 
chromoso
me 10 
open 
reading 
frame 58 
0.0013 +   36.00 
NM_03233
3:exon5:c.
G491A:p.R
164Q 
0.56 
G 1 
N/A N/A 
10 
1052
1830
1 C G 
CALH
M1 
calcium 
homeostasi
s 
modulator 
1 
0.0001 +   16.88 
NM_00100
1412:exon
1:c.G208C:
p.V70L 
-
0.29 
A 1 
N/A N/A 
10 
1057
2757
2 C G SLK 
FYN 
oncogene 
related to 
0.0000 + + 20.60 
NM_01472
0:exon1:c.
C69G:p.H2
-
0.29 A 1 
0.182 0.774 
48 
 
 
SRC, FGR, 
YES 
3Q 
ǂ1
0 
1057
9739
7 G A 
COL1
7A1 
collagen, 
type XVII, 
alpha 1 
0.0005   + 14.75 
NM_00049
4:exon46:c.
C3205T:p.
R1069W 
0.57 
G 1 
N/A N/A 
10 
1058
9343
6 T G 
WDR9
6 
WD repeat 
domain 96 
0.0005 +   23.90 
NM_02514
5:exon35:c.
A4538C:p.
D1513A 
-
0.29 
A 1 
0.048 0.988 
11 
4001
24 C G PKP3 
plakophilin 
3 
0.0013 + + 12.37 
NM_00718
3:exon6:c.
C1431G:p.
N477K 
-
0.71 
G§ 0 
N/A N/A 
11 
7307
4872 G A 
ARHG
EF17 
Rho 
guanine 
nucleotide 
exchange 
factor 
(GEF) 17 
0.0003 + + 18.47 NM_014786:exon16:c.
G5327A:p.
C1776Y 
1.13 
D§ 0 
0.162 0.931 
11 
1082
7786
1 C T 
C11or
f65 
chromoso
me 11 
open 
reading 
frame 65 
0.0064 + + 21.30 
NM_15258
7:exon4:c.
G190A:p.A
64T 
1.13 
C 1 
N/A N/A 
11 
1247
4285
1 G A 
ROBO
3 
roundabout
, axon 
guidance 
receptor, 
homolog 3 
(Drosophila
) 
0.0004 + + 20.20 NM_02237
0:exon9:c.
G1402A:p.
V468M 
1.31 
A 0 
-
0.019 
0.993 
49 
 
 
11 
1261
4703
5 T G 
FOXR
ED1 
FAD-
dependent 
oxidoreduct
ase domain 
containing 
1 
0.0013 + + 18.40 NM_017547:exon10:c.
T1171G:p.
L391V 
-
0.58 
F 1 
-
0.152 
0.815 
ǂ1
2 
2968
094 G T 
FOXM
1 
forkhead 
box M1 
0.0000 + + 13.37 
NM_20200
3:exon8:c.
C1957A:p.
P653T 
0.29 
D§ 0 
0.885 0.615 
*12 
1263
0140 T G 
DUSP
16 
dual 
specificity 
phosphatas
e 16 
0.0026 +   16.34 
NM_03064
0:exon7:c.
A1625C:p.
D542A 
-
0.69 
B§ 2 
-
0.324 
0.686 
*12 
4949
8284 T G 
LMBR
1L 
limb region 
1 homolog 
(mouse)-
like 
0.0040 +   16.10 
NM_01811
3:exon5:c.
A382C:p.M
128L 
0.83 
F 2 
0.156 0.824 
12 
5633
5802 T C DGKA 
diacylglyce
rol kinase, 
alpha 
80kDa 
0.0000   + 17.40 
NM_00134
5:exon16:c.
T1271C:p.
V424A 
1.11 
D 0 
0.551 0.544 
*12 
9637
4381 C A HAL 
histidine 
ammonia-
lyase 
0.0006 + + 25.70 
NM_00210
8:exon17:c.
G1472T:p.
G491V 
1.14 
D§ 1 
-
0.479 
0.922 
12 
1261
3906
9 C T 
TMEM
132B 
transmemb
rane 
protein 
132B 
0.0002 + + 10.88 
NM_05290
7:exon9:c.
C3050T:p.
S1017L 
1.14 
D 0 
-
2.626 
0.023 
15 
7501
4793 T A 
CYP1
A1 
cytochrome 
P450, 
0.0003 + + 14.09 NM_00049
9:exon2:c.
0.83 
F 1 
N/A N/A 
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family 1, 
subfamily 
A, 
polypeptide 
1 
A646T:p.S
216C 
16 
4494
49 G A NME4 
non-
metastatic 
cells 4, 
protein 
expressed 
in 
0.0000   + 11.74 NM_005009:exon3:c.
G296A:p.R
99H 
0.85 
B§ 1 
-
0.076 
0.943 
*16 
2133
701 G A TSC2 
tuberous 
sclerosis 2 
0.0040 +   12.84 
NM_00111
4382:exon
32:c.G3820
A:p.A1274
T 
0.85 
B§ 1 
-
0.229 
0.658 
16 
1178
5220 G A 
TXND
C11 
thioredoxin 
domain 
containing 
11 
0.0014 +   18.28 
NM_01591
4:exon8:c.
C1826T:p.
A609V 
0.85 
B§ 1 
0.134 0.896 
16 
2079
6338 G A 
ACSM
3 
acyl-CoA 
synthetase 
medium-
chain 
family 
member 3 
0.0013 + + 22.00 NM_005622:exon8:c.
G1052A:p.
S351N 
0.57 
G 0 
0.751 0.496 
16 
5332
1892 A G CHD9 
chromodo
main 
helicase 
DNA 
binding 
protein 9 
0.0076   + 18.22 NM_025134:exon27:c.
A5213G:p.
K1738R 
0.65 
G 0 
0.095 0.910 
51 
 
 
17 
5425
076 A G 
NLRP
1 
NLR family, 
pyrin 
domain 
containing 
1 
0.0042   + 10.35 
NM_03300
7:exon12:c.
T3461C:p.
M1154T 
-
0.56 
D§ 0 
0.293 0.727 
17 
4876
2223 G A 
ABCC
3 
ATP-
binding 
cassette, 
sub-family 
C 
(CFTR/MR
P), 
member 3 
0.0013 + + 22.70 NM_00378
6:exon29:c.
G4267A:p.
G1423R 
0.85 
B§ 0 
-
0.043 
0.994 
17 
6143
2613 T A 
TANC
2 
tetratricope
ptide 
repeat, 
ankyrin 
repeat and 
coiled-coil 
containing 
2 
0.0000 + + 25.00 NM_02518
5:exon12:c.
T2222A:p.
F741Y 
0.85 
B§ 0 
-
0.213 
0.859 
19 
1159
8418 G A 
ZNF6
53 
zinc finger 
protein 653 
0.0000   + 16.16 
NM_13878
3:exon4:c.
C860T:p.A
287V 
1.41 
A 1 
0.168 0.829 
19 
1322
6094 G A 
TRMT
1 
TRM1 
tRNA 
methyltrans
ferase 1 
homolog 
(S. 
cerevisiae) 
0.0002 + + 20.70 NM_01772
2:exon4:c.
C640T:p.R
214W 
1.41 
A 1 
0.222 0.737 
52 
 
 
19 
5717
5814 C G 
ZNF8
35 
zinc finger 
protein 835 
0.0009 +   18.91 
NM_00100
5850:exon
2:c.G753C:
p.E251D 
0.86 
G 1 
-
0.797 
0.556 
19 
5772
3459 C T 
ZNF2
64 
zinc finger 
protein 264 
0.0000 + + 11.70 
NM_00341
7:exon4:c.
C994T:p.R
332W 
0.86 
G 1 
-
0.132 
0.882 
20 
4446
3002 A G 
SNX2
1 
sorting 
nexin 
family 
member 21 
0.0000 +   22.20 
NM_15289
7:exon2:c.
A184G:p.S
62G 
0.85 
B§ 1 
-
0.220 
0.797 
6 1533
1234
3 
TT
TT
A 
T MTRF
1L 
mitochondri
al 
translationa
l release 
factor 1-like 
0.0000 
NA 
+ 
(SIFT
-
INDE
L) 
14.77 
NM_01904
1:exon6:c.9
15_918del:
p.305_306
del 
0.57 G 1 -
0.095 
0.924 
53 
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Of the 68 retained variants, five variants (found in the genes GSTCD, DUSP16, 
LMBR1L, HAL, and TSC2) were found in definite IAs in two families; in all of 
these cases, the variant segregated fully with definite IA in only one family. Two 
other variants (found in the genes COL17A1 and FOXM1) were the only variants 
of the 68 retained variants that were labeled with vascular-related GO 
annotations (i.e. GO:0005604 basement membrane and GO:0005581 collagen; 
and GO:0001570 vasculature development and GO:0001570 vasculogenesis; 
respectively). 
 
Linkage 
The distribution of genome-wide LOD scores for each family is depicted in 
Figures 6-12, with the WES variants satisfying biological filters 1-6 
superimposed. The maximum possible LOD score for each family given the 
model parameters and the specific pedigree structure is also reported in Figures 
6-12. The highest LOD score obtained by linkage markers within a 10Mb window 
centered on each sequencing variant is recorded in Table 6. Of the 68 WES 
variants satisfying biological filters 1-6 and manual inspection, 23 variants had a 
LOD score for a linkage marker within 10Mb of the sequencing variant that fell 
within 0.01 of the highest possible LOD score for that family. 
 
 
 
Figure 6. Summary of genome-wide multipoint linkage analysis for intracranial aneurysm whole exome 
sequencing Family A. Positions of candidate single nucleotide variants and insertion/deletions identified in the 
sequencing data are denoted by diamonds and crosses, respectively. 
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Figure 7. Summary of genome-wide multipoint linkage analysis for intracranial aneurysm whole exome 
sequencing Family B. Positions of candidate single nucleotide variants and insertion/deletions identified in the 
sequencing data are denoted by diamonds and crosses, respectively. 
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Figure 8. Summary of genome-wide multipoint linkage analysis for intracranial aneurysm whole exome 
sequencing Family C. Positions of candidate single nucleotide variants and insertion/deletions identified in the 
sequencing data are denoted by diamonds and crosses, respectively. 
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Figure 9. Summary of genome-wide multipoint linkage analysis for intracranial aneurysm whole exome 
sequencing Family D. Positions of candidate single nucleotide variants and insertion/deletions identified in the 
sequencing data are denoted by diamonds and crosses, respectively. 
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Figure 10. Summary of genome-wide multipoint linkage analysis for intracranial aneurysm whole exome 
sequencing Family E. Positions of candidate single nucleotide variants and insertion/deletions identified in the 
sequencing data are denoted by diamonds and crosses, respectively.  
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Figure 11. Summary of genome-wide multipoint linkage analysis for intracranial aneurysm whole exome 
sequencing Family F. Positions of candidate single nucleotide variants and insertion/deletions identified in the 
sequencing data are denoted by diamonds and crosses, respectively.  
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Figure 12. Summary of genome-wide multipoint linkage analysis for intracranial aneurysm whole exome 
sequencing Family G. Positions of candidate single nucleotide variants and insertion/deletions identified in the 
sequencing data are denoted by diamonds and crosses, respectively. 
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The 23 variants within a possible linkage peak were distributed among all 
families except family F, where the highest LOD score for a linkage marker within 
10Mb of a filtered sequencing variant was 0.83 but the highest possible LOD 
score for the family was 1.12. Family B had the most retained variants within 
possible linkage peaks (n=9); followed by family D (n=4); families A, E, and G 
(n=3); and family C (n=1). Of the 23 variants, only 8 also met the optional 
prioritization criteria of segregating with all aneurysmal phenotypes and not being 
carried by an unaffected individual (KLF11 variant in family A, variants in ABCC3 
and TANC2 in family B, variants in ALMS1 and ARHGEF17 in family D, and 
variants in SMEK2, HTRA2, and NDST1 in family E). 
 
While none of the 68 variants coincided with well-established GWAS association 
signals, 6 of the variants were found within IA linkage peaks identified in 
previously published family studies, independent of the families in this report. 
Four variants (found in the genes C1orf38, PTAFR, ZNF362, and MAP7D1) fell 
within the linkage peak 1p34.3-36.13,90,91 while 2 variants (found in the genes 
ROBO3 and FOXRED1) were located in the linkage peak 11q24-25 93-95. None of 
these 6 genes were suggested as candidate genes by the authors of the 
published linkage studies. The linkage regions each cover hundreds of genes, as 
they span approximately 24 and 14 Mb respectively. 
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RNA expression 
Expression data was obtained in 51 of the 68 candidate genes in an independent 
set of IA cases and controls. Log fold changes and FDR-adjusted p-values for 
each gene is displayed in Table 6. Only 1 gene (TMEM132B) of the 51 genes 
showed differential expression (overexpressed with log fold change=2.63, FDR-
adjusted p-value=0.023). 
 
Discussion 
TMEM132B 
Exome sequencing presents an opportunity to explore the contribution of rare 
variation to complex disorders like IA. We have used this approach to identify 68 
rare variants in 68 genes that segregate within 7 densely affected families. Of the 
51 genes that were expressed in IA tissue, one gene (TMEM132B) was found to 
be significantly overexpressed in IA tissue in comparison to control vascular 
tissue. 
 
TMEM132B, or transmembrane protein 132B, is a relatively uncharacterized 
protein of unknown function. The variant segregating in the family is rare (0.024% 
frequency in European American samples in the Exome Sequencing Project and 
not found in 1000 Genomes) and predicted damaging by SIFT, PolyPhen-2, and 
CADD due to a change from the polar amino acid serine to the nonpolar amino 
acid leucine at a highly conserved position. Each of the individuals with a definite 
IA in family D was heterozygous for the variant. Mutations inherited in a dominant 
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manner often lead to a disease phenotype through a gain of function mechanism, 
which would be supported by the overexpression of TMEM132B in IA tissue as 
compared to control vessels. It is also possible, however, that dominantly-
inherited mutations exert their effect via haploinsufficiency or dominant negative 
mechanisms. Further studies are required to confirm the role of TMEM132B in IA 
and through what mechanism the variant identified in this study may act. 
 
The TMEM132B variant was not inherited by individual 11 in family D. Individual 
11 was diagnosed as a possible IA due to the presence of a small aneurysm 
identified through non-invasive imaging (i.e. 1-2mm, verified by 3 independent 
neurologists). This is in contrast to the definite IAs clearly identified in this 
individual’s sibling and cousins; thus, individual 11 is most likely actually 
unaffected. 
 
Prioritization of variants within families 
Expression information was only available for 51 of the 68 candidate genes; thus, 
RNA expression cannot confirm or rule out the role of the remaining 17 genes in 
IA pathophysiology. Additionally, a subset of the other 50 variants with 
expression data may also contribute to IA in ways not captured by the RNA 
expression experiment and should be explored. In order to further study the 
cause of IA in each of the remaining families, candidate variants in each family 
must be prioritized. 
 
65 
 
In families C and E, segregation analysis reduced the number of prioritized 
variants to only 2 and 4 variants, respectively. For family C, the two variants have 
a CADD score >20. The variant in SEC16B is not found within a potential linkage 
peak; however, in support of its potential significance in disease susceptibility, it 
is not carried by any tested unaffected family member. The variant in C11orf65, 
on the other hand, is found within a potential linkage peak but is also inherited by 
an unaffected family member. For family E, three variants segregate in the family 
(and a fourth variant in GSTCD is found in only one individual in family E but 
segregates fully in family G). The three variants that segregate in the family (in 
genes SMEK2, HTRA2, and NDST1) all are found within potential linkage peaks. 
Data are not available from any unaffected family members. Therefore, further 
prioritization among these three variants could incorporate CADD scores, which 
range from 11.98 for the HTRA2 variant to 23.9 for the SMEK2 variant. 
 
Considerations for pedigree and phenotypic data 
It is possible that genetic heterogeneity, phenocopies, or gene-environment 
interactions could explain one or more IAs in the families chosen for this study. In 
this case, the criterion requiring all affected individuals to share a variant would 
miss important disease-contributing variants. Similar family-based sequencing 
studies in the future could relax this segregation criterion with the recognition that 
a much larger number of variants will be retained. Family-based aggregative 
association tests that incorporate different penetrance models could also be 
employed with a larger number of samples. 
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The availability and quality of clinical data is also critical to consider in complex 
disease WES studies. In this study, several families also had individuals with 
probable and possible IAs (see Table 3 for phenotype definitions), and one family 
also had an occurrence of an abdominal aortic aneurysm (Figure 5). Given the 
high density of definite IAs in these families, it is likely that some or all of the 
probable and possible IAs have disease due to the same disease-contributing 
variant. Additionally, given the possible genetic link between different forms of 
aneurysms,109 the abdominal aortic aneurysm may also share the same genetic 
etiology within that family. We thus flagged variants that segregated fully among 
all individuals with an aneurysm (definite, probable, or possible IA, or an 
abdominal aortic aneurysm) (Tables 4-5). This represents a possible method for 
prioritizing variants for further study, with the caveat that including non-definite 
IAs increases the likelihood of genetic heterogeneity, phenocopies, and gene-
environment interactions. 
 
Another approach to prioritize variants for further study is to utilize genotypic data 
from unaffected individuals. The ability of this approach to rapidly narrow down 
the number of variants under consideration is readily apparent from this study 
(Tables 4-5), but there are major concerns about inflating false negative rates by 
using unaffected individuals. Given the traditionally late age of onset for 
intracranial aneurysms, only individuals who had an MRA confirming the absence 
of IA at age 45 or older were sequenced as unaffected samples. Despite these 
precautions, the unaffected individuals in this study were still relatively close in 
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age to the age at diagnosis of their relatives who had an IA, and it is possible that 
the unaffected individuals will actually develop an IA later in life due to a genetic 
predisposition. 
 
The difficulty in defining an unaffected also surfaces when considering the 
putative obligate carriers in these families. In Family A, individual A-7 also had an 
MRA done at age 64 that excluded the presence of an IA, yet we would posit that 
this individual likely passed a causative genetic variant to her daughter (A-10), 
whose IA is more likely to have a genetic basis due to her young age of onset. 
Without the daughter’s data, individual A-7 would have likely been chosen as an 
unaffected individual for sequencing, especially given that she had major 
environmental risk factors (a history of smoking and hypertension). In Family E, 
the sequenced individual E-9 is also an obligate carrier under our model. Unlike 
individual A-7, an MRA could not be obtained on individual E-9, and she did not 
have a history of smoking or hypertension. Since all affected individuals in family 
E had at least one environmental risk factor and individual E-9 did not, it is 
possible that the causative genetic variant in family E requires an additional 
environmental insult to lead to IA development. The importance of strong 
environmental risk factors such as smoking to the development of aneurysms, 
even in the context of rare causal genetic variants, cannot be underestimated. 
Alternative methods of prioritization of variants that incorporate this possibility 
should be explored. Thus, unaffected status in this study was used as a 
mechanism for possible prioritization but not for automatic exclusion of variants. 
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The ability to use unaffected individuals will vary in studies of different diseases 
and will likely be more fruitful in those diseases that appear to have a smaller 
environmental/lifestyle contribution. 
 
For future family-based sequencing studies in complex disease, it may not be 
feasible to sequence as many individuals per pedigree as was done for this 
study. Thus, it is critical to carefully select samples based on the quality of 
phenotyping and the pedigree structure. Recently developed tools offer statistical 
methods to select related subjects for sequencing based on genetic distance,110 
samples that span multiple generations (Exome Picks, 
http://genome.sph.umich.edu/wiki/ExomePicks), and a combination of both of 
these methods.111 As evident from Tables 4-5, selecting families with more 
closely related individuals, such as families with full siblings as in Families F and 
G, will yield a smaller number of initially called variants across the family. Yet, the 
power to narrow down the number of variants segregating with disease is 
diminished in such families due to the naturally larger percentage of alleles 
shared, as compared to families with individuals in multiple generations such as 
in Family C. Thus, where possible, selection of more distantly related family 
members for sequencing studies will have greater power to generate a narrowed 
list of prioritized variants.  
 
For some families, it may be possible to combine linkage and sequencing data to 
find causative variants. The families sequenced in this study were included as a 
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part of a larger linkage study reported previously.92 The same model parameters 
used for WES variant filtering was applied for multipoint linkage analysis. Since 
any given marker may have been uninformative for a family, a maximum LOD 
score was reported within a 10Mb window of the sequence variant’s 
chromosomal position. Although only modest evidence of linkage was obtained, 
several sequencing variants lay within the linkage regions in these families 
(Figures 6-12). Many variants, however, did not overlap with any evidence of 
linkage, suggesting that these families were either not fully informative for robust 
linkage analysis near these loci, or the sequencing variants identified are not 
causative genetic variants in these families. 
 
Considerations for exonic variation 
In recent years, WES has emerged as a practical method for systemically 
exploring rare coding variation. Since the majority of known genetic causes of 
Mendelian disorders affect protein coding regions,31 the exome is a logical 
starting place to identify potentially causative variants in diseases that exhibit 
Mendelian inheritance. The densely-affected families sequenced in this study 
appear to display autosomal dominant inheritance; therefore, we hypothesized 
that coding variants may explain most or even all of these cases. 
 
Due to imperfect capture and alignment, WES generates some off-target, non-
exonic variant calls. While it is possible that important variation exists in these 
off-target regions, a higher percentage of calls in these regions are of poorer 
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quality. Thus, only those variants within exonic or splicing regions were retained 
in this experiment. Since different databases contain different numbers of and 
boundaries for genes and exons,112 a consensus prediction of gene and exon 
boundaries was made to determine those variants that fell within exonic or 
splicing regions. In order to minimize the type I error rate by using functional 
predictions of the highest confidence, the intersection of functional predictions 
from three different databases (RefSeq, UCSC, and Ensembl) was used for this 
study. Thus, variants were only retained if they were predicted by all three 
databases to be within exonic or splicing regions. Other WES studies may 
choose to generate a larger set of variants by prioritizing all variants in the union 
rather than the intersection of functional predictions from multiple databases; 
however, appropriate methods for validating variants with functional predictions 
that differ by database should be employed. 
 
It is possible that non-coding variants and/or epistatic interactions are important 
in IA development in these families and in other complex diseases, in which case 
alternate study designs should be utilized. At the time of this study, whole 
genome sequencing could have only been employed at the expense of 
sequencing fewer individuals, and annotations and bioinformatics tools available 
for non-coding sequence were less robust. Given that whole genome sequencing 
generates about 3 million SNVs per genome,113 annotations and bioinformatics 
tools are even more critical for practical prioritization of candidate variants. In the 
future, techniques like whole genome sequencing, as well as targeted 
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resequencing, transcriptome sequencing, and other high throughput study 
designs, can be applied to fully catalogue the role of genetic variation in IA 
development. 
 
Considerations for allele frequency 
The average individual has around 15,000 exonic SNVs differing from the 
reference human genome sequence.103 In order to narrow down the number of 
variants identified by a WES study, initial studies34,35 focused on rare diseases 
and limited analysis to novel variants. This strategy is too restrictive for more 
common diseases such as IA. In the particular subset of families used for this 
study, there is a uniquely high incidence of IA, which enriches for the possibility 
of identifying rare, highly penetrant variants of larger effect sizes. Rare variants 
and less common variants are typically defined as less than 1% and 1-5% minor 
allele frequency, respectively.114,115 Given the rarity of families that are as 
densely affected as the ones in this study, a 1% minor allele frequency threshold 
was set. It is possible, however, that a variant of higher minor allele frequency 
causes IA in one or more of these families. Future studies with a much larger 
sample size could employ aggregative association tests42 with relaxation of the 
allele frequency threshold. 
 
In this study, allele frequencies specifically from European American populations 
were available from public databases. Given that rare variants can be population-
specific,116 the selection of appropriate allele frequency databases is critical. In 
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lieu of publicly available allele frequencies, future studies may consider 
sequencing a large number of internal controls and possibly requesting 
commonly available controls to sequence as well. While not feasible for the 
current study, such a design would help control for platform- and pipeline-specific 
artifacts in sequencing while ensuring phenotyping quality for controls. 
 
While it is standard for WES studies to utilize public databases to filter variants, it 
is also valuable to use internal frequency databases that are specific to the 
sequencing and variant calling pipeline. Because variant calling can be lab-
specific due to the technology used, in this study variants were annotated for 
binned minor allele frequencies from 290 unrelated samples without a known 
cardiovascular phenotype that were exome sequenced at CIDR. Thus variants 
that would have otherwise been considered rare or novel when compared 
against public databases, but that were actually a recurring artifact of the 
sequencing, were captured as having a high CIDR binned minor allele frequency. 
Given that the bioinformatics pipeline used in this study differed slightly from that 
of the internal database, the internal database filter may have missed some 
artifacts specific to the variant calling method. Variants that were monomorphic 
(i.e. all heterozygous or homozygous for the alternate allele) across all samples 
were also removed since it is highly unlikely that the identical rare disease-
causing allele would be shared by both affected and unaffected individuals in 
multiple families. 
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Indel allele frequencies in both internal and external databases are inherently 
less accurate than frequencies for SNVs, due to the increased difficulty and 
variation in calling structural variants. Also, differences in how position 
coordinates are assigned as well as reference and alternate allele designations 
further makes comparison challenging. The 26 indels that passed biological 
filters 1-6 (described in the Methods) in all cases except for one were shared in 
almost all or all of the 7 families sequenced in this study. Just as variants that 
were monomorphic across all datasets were removed as probable sequencing or 
pipeline artifacts, it is very unlikely that any given rare disease-causing 
insertion/deletions would also be shared across all or almost all families in a 
complex disease. It is possible that multiple families may carry different disease-
causing insertion/deletions in the same gene, but this pattern was not seen. 
Thus, a second internal frequency comparison set of 500 samples that had a 
more similar bioinformatics pipeline to the IA samples sequenced in this study 
(i.e. use of GATK Unified Genotyper for variant calling) was used for manual 
review in combination with IGV visual inspection for the 26 indels remaining after 
application of biological filters. Manual review as described in the Methods 
excluded all but one of the 26 indels, demonstrating that manual inspection and 
use of an internal dataset generated by a similar bioinformatics pipeline are 
critical for reviewing insertion/deletions in sequencing experiments. Future 
studies may also consider utilizing newer local re-assembly-based methods for 
variant calling, such as FreeBayes117 or GATK’s HaplotypeCaller, which may 
improve the accuracy of insertion/deletion calls. 
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Considerations for functional predictions of exonic variation 
More severe amino acid substitutions are more likely to present clinically,31 so 
most WES studies to date have focused on non-synonymous SNVs and 
insertion/deletions. In this study, we also opted to focus on these variants, as 
predicted by the intersection of the three gene databases (RefSeq, UCSC, and 
Ensembl). Future studies focused on exonic variation could also study the effect 
of synonymous variation, which has been shown to also play an important role in 
human disease.118 At the time of this study, fewer validated tools existed to 
examine the role of synonymous variation in sequencing data. 
 
In this study, several programs were used to measure the level of conservation of 
a locus and the predicted pathogenicity of a variant. The programs have varying 
degrees of sensitivity and specificity for different kinds of variants, particularly 
due to the use of different but not completely independent data sources when 
generating predictions.79 The bioinformatics community is working to develop 
tools that will be able to better integrate information to provide a more informed 
pathogenicity prediction. One such tool, the CADD program,46 was recently 
introduced but has not been applied to a large number of datasets. Since there 
are few published studies implementing CADD, we have conservatively removed 
only variants with a C-score <10, thus retaining variants that are predicted by 
CADD to be among the 10% most deleterious substitutions in the human 
genome. 
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Considerations for biological processes and pathways 
The filtering schema did not employ any assumptions about biological processes 
or pathways. Variants were annotated for GO terms chosen for possible relation 
to IA formation; however, only two variants in the final candidate variant list 
(variants found in the genes COL17A1 and FOXM1) had one or more of these 
GO annotations. While using GO annotations as a filter is a powerful method for 
narrowing a list of variants, such an approach would depend on the 
comprehensiveness of GO annotations, as well as the reliability of investigator-
chosen GO terms. To avoid subjectivity in selecting biological processes or 
pathways, future studies with larger sample sizes should consider employing 
formal gene set enrichment analysis, which eliminates the need to choose 
pathways a priori. Even for smaller datasets, use of GO annotations may help 
determine which gene variants to pursue first in additional experiments to explore 
possibly causal associations between the variant and disease of interest. 
 
Summary 
This is one of the few studies published to date that apply WES in a cohort of 
well-characterized families densely affected with a common complex disease 
without an a priori focus on a particular pathway or genomic region. We have laid 
out many considerations for future WES studies in complex disease, including 
the use of pedigree and phenotypic data, defining gene and exon boundaries, 
sources for allele frequency estimates, proper interpretation of in silico functional 
predictions, the role of environmental factors in the determination of potentially 
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causal rare variants, and the possible utility of combining pathway information 
with sequencing data. 
 
In this study, 68 rare exonic variants in 68 genes were identified. Of these genes, 
one gene (TMEM132B) was significantly differentially expressed in IA versus 
control tissue. Further studies are needed to confirm and explore the TMEM132B 
variant, as well as the possible contribution of the other 67 variants. Replication 
and/or meta-analysis with similar sequencing studies using larger sample sizes 
could be used to gather further evidence for specific genes on this list. 
Additionally, a subset of these variants, which can be prioritized through any of 
the methods discussed in this study, could be explored through functional studies 
in models where vascular phenotypes can be easily observed, such as zebrafish. 
Targeted gene editing, such as through the CRISPR-Cas system, could help test 
whether a given variant disrupts the normal functioning of the relevant gene and 
whether such a disruption leads to a phenotype of interest. Ultimately, such a 
model should also enable investigation of whether the disrupted phenotype can 
be rescued by reintroduction of the wild type allele or interference with the variant 
allele. For comprehensive exploration of the variants identified in this study, 
multiple methods of experimental validation may be necessary. This study 
represents a necessary first step in the evaluation of role of rare variants in a 
common complex disease. Further evaluation in other familial and sporadic 
samples, as well as multi-ethnic samples, will be essential  
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CHAPTER II: PARKINSON DISEASE 
 
Introduction 
Parkinson’s disease (PD) is a progressive neurodegenerative disease for which 
susceptibility is linked to genetic and environmental risk factors. Linkage studies 
have previously identified very rare variants in multigenerational families119-123 
that have a large effect on disease risk. Genome-wide association studies have 
recently revealed common loci that have relatively small individual effects on PD 
susceptibility.113,124 Despite these advances, currently only about 6-7% of the 
heritability of PD has been explained.125  
 
One approach to identify other potential genes and variants contributing to 
disease risk is through the analysis of personal genomes using high-throughput 
sequencing to highlight variants that exert a significant effect on disease 
susceptibility. The likelihood of detecting such variants can be enriched through 
the sequencing of PD patients with a family history of PD, who may be more 
likely to have a genetic contribution to disease susceptibility. Whole exome 
sequencing (WES) typically yields over 20,000 exonic single nucleotide variants 
(SNVs) per individual sequenced,30 requiring a strategy to narrow the number of 
variants of interest. Successful approaches have included aggregative 
association tests in large samples of unrelated individuals65,126,127 and filtering 
strategies within large and densely affected pedigrees128,129 or consanguineous 
families.130 Cohort studies of unrelated individuals are potentially limited by the 
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cost of WES in large numbers of subjects. While family-based strategies facilitate 
variant prioritization based on allele sharing and segregation, they are potentially 
insensitive to incompletely penetrant variants, intra-familial heterogeneity, and 
oligogenic inheritance, all of which are considerations in complex genetic 
disorders such as PD.131 
 
WES in PD has been reported in studies involving one or a few families128,129,132-
135 or in candidate gene investigations.136 In this report, we sequenced exomes 
from a discovery cohort of 93 individuals in 32 multiplex PD families. We then 
analyzed the genes with variants of interest in a replication cohort of familial PD 
probands to identify a subset of candidate genes containing rare, potentially 
functional variants that may contribute to disease risk (Figure 13). 
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Figure 13. Parkinson disease whole exome sequencing study design. 
DISCOVERY COHORT 
• Sequence families 
• Retain rare, functional, variants predicted to be 
damaging that segregate with disease 
• Retain genes in functional pathways that are 
expressed in the brain and have variants seen in ≥5 
families 
REPLICATION COHORT 
• Retain rare, functional, variants predicted to be 
damaging 
• Catalogue variation observed in the replication 
cohort in the genes  identified in the discovery 
cohort 
VALIDATE VARIANTS 
• Validate all variants identified in the discovery or 
replication cohorts in the replicated genes 
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Materials and methods 
Discover cohort subjects 
The study protocol was approved by the Indiana University Institutional Review 
Board (IRB) as well as the ethics boards of all study sites. Families with at least 
one pair of living siblings diagnosed with PD were recruited and evaluated 
throughout North America by Parkinson Study Group (PSG) movement disorder 
neurologists. Written informed consent was obtained from all participants. 
Validated diagnostic checklists137,138 implementing UK PD Brain Bank (UKPDBB) 
criteria, modified to allow for familial PD, were completed for all study 
participants. PD patients were classified as having either verified PD (VPD) or 
non-verified PD (NVPD).  NVPD cases displayed clinical symptoms similar to PD 
but either failed to meet all UKPDBB inclusion criteria or met at least one of the 
exclusion criteria. All study subjects were offered the opportunity to participate in 
a brain-only autopsy program. Peripheral blood for DNA extraction was obtained 
from all consented individuals. 
 
Exome sequencing of discovery samples 
WES was performed on 32 families with the largest number of VPD cases, 
without another segregating neurological disorder, and without a known 
causative PD mutation in LRRK2 or parkin. Among the 32 families were 90 
subjects meeting criteria for VPD who were included for sequencing. An 
additional 3 individuals who were initially classified as NVPD were also included. 
Two of these individuals had subsequent neuropathological findings consistent 
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with PD. The third subject met all PD clinical inclusion criteria (including onset 
after 20 years of age, bradykinesia, persistent asymmetry, diagnosis by a 
movement disorder neurologist) and had significant supporting criteria (including 
rigidity, postural instability, a resting tremor, disease progression, and a positive 
response to levodopa) but met the solitary exclusion criterion of having 
concomitant Alzheimer disease and sensory deficits. For the purposes of 
subsequent analyses, this individual was considered to be affected. Of the 32 
families, 6 families had 2 affected members sequenced, 23 families had 3 
affected members sequenced, and 3 families had 4 affected members 
sequenced. 
 
All samples were sequenced at one of two centers (44 samples representing 15 
families at the Center for Inherited Disease Research [CIDR], and 53 samples 
representing 18 families at the HudsonAlpha Institute for Biotechnology). One 
family with 4 members was sequenced at both centers for quality assurance. The 
Agilent SureSelect 50Mb Human All Exon Kit (CIDR) and Nimblegen 44.1Mb 
SeqCap EZ Exome Capture version 2.0 (HudsonAlpha) were used for capture, 
and the Illumina HiSeq 2000 system was used for 100bp paired-end sequencing. 
 
For the one family sequenced at both centers, summary sequencing statistics 
were compared to assess quality. Because two different captures were used, 
statistics were calculated only for those loci targeted by both capture kits. The 
intersection of variants found at both sequencing centers (32,280) and those sets 
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of SNVs found only at one center (3,061 for CIDR and 640 for HudsonAlpha) 
were examined. For SNVs found at the intersection, the genotype concordance 
rate was 99.0%, transition/transversion ratio was 3.0, and 99.0% were found in 
dbsnp137. Of those SNVs only identified at CIDR, the transition/transversion 
ratio was 2.4, and 98.3% were found in dbSNP137. For those SNVs found only 
at HudsonAlpha, the transition/transversion ratio was 1.8, and 86.1% were 
identified in dbSNP137. 
 
Samples were aligned to the human genome reference sequence (build hg19) 
using Burrows Wheeler Aligner43. The Genome Analysis Toolkit (GATK)44 was 
used for local realignment, base quality score recalibration, and multi-sample 
variant calling (Unified Genotyper) for the samples sequenced at CIDR and 
HudsonAlpha separately. GATK Variant Quality Score Recalibration102 and 
recommended GATK training sets (i.e. HapMap 3.3 and Illumina Omni 2.5M chip 
sites, available from GATK bundle 1.2) were used to create a high-quality set of 
variant calls.  
 
Annotation 
ANNOVAR54 was used to annotate high quality variants for predictions of variant 
location and function (using the RefSeq and UCSC databases). Custom scripts 
annotated variants for their allelic frequency in 1000 Genomes European 
American populations (2012 release, http://www.1000genomes.org)36, Exome 
Sequencing Project (ESP) European American populations (5400 exomes 
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release, http://evs.gs.washington.edu/EVS/)103, and dbSNP 137 
(http://www.ncbi.nlm.nih.gov/SNP/)139. Allele frequencies were also obtained from 
an internal frequency database of 283 unrelated samples without a known 
neurological phenotype sequenced at CIDR. SIFT52, Polyphen250, MutPred49, 
and Gerp48 were used to predict mutation deleteriousness and degree of locus 
conservation. Custom scripts annotated genes that fell within Gene Ontology 
(GO) (http://www.geneontology.org)104 categories of interest (GO:0042417 
dopamine metabolic process, GO:0050780 dopamine receptor binding, 
GO:0007270 neuron-neuron synaptic transmission, GO:0050804 regulation of 
synaptic transmission, GO:0007212 dopamine receptor signaling pathway, 
GO:0004952 dopamine receptor activity, GO:0006511 ubiquitin-dependent 
protein catabolic process, GO:0006979 response to oxidative stress, 
GO:0016567 protein ubiquitination, GO:0031396 regulation of protein 
ubiquitination). Genes were determined to be expressed in the brain based on 
significant expression above the background, as computed and normalized 
across Allen Brain Institute samples, following the Allen Human Brain Atlas 
protocols (http://www.brain-map.org, downloaded 05/17/2012). 
 
Filtering 
Variants were retained if they were: 1) predicted to be SNVs or 
insertion/deletions (indels) in an exonic and/or splicing region based on one or 
more gene databases; 2) had an allele frequency <3% in European American 
reference populations in 1000 Genomes and ESP, as well as in the internal 
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frequency database; 3) were predicted damaging by at least one in silico protein 
functional and structural effect prediction program or were located in a highly 
conserved region (Gerp>0.5); and 4) segregated with at least two PD cases in 
the same family. Genes were then retained if they:  A) were in a GO category of 
interest; B) were expressed in the brain; and C) had retained variants that were 
observed in at least 5 of the 32 families sequenced. 
 
Replication and variant confirmation 
The prioritized genes were examined in a replication cohort of 49 unrelated PD 
patients with a family history of PD that had WES performed at the Human 
Genome Sequencing Center (HGSC) at Baylor College of Medicine (BCM) 
through the Baylor-Hopkins Center for Mendelian Genomics initiative. All 
individuals were clinically diagnosed with PD based on examination by 
experienced movement disorders neurologists and reported at least one first-
degree relative diagnosed with PD.  Written informed consent was obtained from 
all participants, and the study was approved by the BCM IRB. Preparation and 
sequencing of genomic DNA was performed as previously described in detail.140  
The BCM HGSC Core-developed library (VCRome 2.1)141 was used for capture 
(covered all genes nominated from the discovery analysis at a depth of 50X or 
greater), and the Illumina HiSeq 2000 system was used for sequencing. With 
sequencing yields averaging 9.9 Gb per sample, samples achieved an average 
of 94% of the targeted exome bases covered to a depth of 20X or greater. 
Sequencing data were processed through the HGSC-developed Mercury pipeline 
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using the Atlas2 variant calling method142,143 and annotated using the Cassandra 
annotation pipeline144 based on ANNOVAR. Compared to the discovery pipeline, 
a more stringent allele frequency filter was employed—all variants considered in 
replication were <1% in European American reference populations (1000 
Genomes and ESP). Potentially deleterious and highly conserved variants were 
identified using SIFT, Polyphen2, MutPred, and Gerp. Variants present in the 8 
genes prioritized from the discovery analysis were extracted. 
 
All variants in replicated genes were reviewed in the Exome Aggregation 
Consortium beta version 0.2 (ExAC, Cambridge, MA 
[http://exac.broadinstitute.org)] [November 17, 2014]) to ensure that allele 
frequencies obtained through the >60,000 exomes in ExAC corresponded to 
those obtained in 1000 Genomes and ESP 5400. Targeted PCR and Sanger 
sequencing were used to confirm all variants for genes with consistent evidence 
supporting links to familial PD in both the discovery and replication cohorts. 
Variants were annotated for C-scores from the Combined Annotation Dependent 
Depletion (CADD) webserver (http://cadd.gs.washington.edu),46 where C-scores 
≥10 correspond to the 10% most deleterious substitutions in the human genome, 
as predicted by CADD. Genes with evidence of replication were also annotated 
for residual variation intolerance score (RVIS) percentiles, in which lower 
percentiles correspond to genes that are most intolerant of functional 
mutations.51 
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Results 
Discovery Cohort 
Clinical characteristics of individuals from the 32 multiplex PD families in the 
discovery cohort are summarized in Table 7. 
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Table 7. Clinical characteristics of the Parkinson disease patients in the 
discovery and replication cohorts. 1 - Data not available for 2 of 93 cases. 
2 - Data not available for 6 of 49 cases. 
Clinical Characteristic Discovery Cohort Replication Cohort 
Number of individuals 
(number of families) 
93 (32) 49 (49) 
% Female, % Male 47.9%, 52.1% 32.6%, 67.3% 
Average age of onset 
(mean ± SD) 
61.8 ± 9.971 50.1 ± 15.72 
Ethnicity 90 self-reported, non-
Hispanic, European 
Americans 
3 self-reported, non-
Hispanic Asians 
37 self-reported, non-
Hispanic European 
8 individuals of Hispanic 
descent 
3 self-reported, non-
Hispanic Asians 
1 individual of Middle 
Eastern descent 
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Each sample sequenced at CIDR achieved a mean coverage of 98X for targeted 
bases, with an average of 93% of targeted bases covered at least 8X. The 
transition/transversion ratio was 3.3, and 94.4% of variants were found in 
dbsnp137. The sequencing data achieved 99.6% concordance with 
OmniExpress GWAS array genotype calls performed on the same individuals. 
Each sample sequenced at HudsonAlpha achieved a mean coverage of 57X for 
targeted bases, with an average of 93% of targeted bases covered at least 8X. 
The average transition/transversion ratio per sample was 3.2, and 91.5% of 
variants were found in dbSNP137. 
 
Application of GATK quality filters resulted in 149,055 SNVs and 9,378 indels 
across all samples (range of 22,188-28,230 total variants per sample) (Figure 
14). Nonsynonymous SNVs or indels within an exon (as annotated by at least 
one of two gene databases, i.e. RefSeq, UCSC) having an allele frequency of 
<3% (1000 Genomes, ESP) were retained. After removing variants that were 
predicted to be benign by all three protein prediction programs and that were not 
in a highly conserved region, approximately 10% of the original variants 
remained. Further filtering was performed based on segregation within families, 
leaving 7,729 SNVs and 305 indels. Prioritization based on brain expression, GO 
annotation, and presence of variants in at least 5 families yielded 21 variants (21 
SNVs, 0 indels) across 8 genes for evaluation in the replication cohort (Table 8).
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Figure 14. Parkinson disease discovery cohort variant filtering. SNV = single 
nucleotide variant; MAF = minor allele frequency; GO = Gene Ontology  
In genes seen across at least 5 families 
21 SNVs 0 indels 
In genes with GO annotation 
228 SNVs 10 indels 
In genes expressed in the brain 
6,384 SNVs 235 indels 
Segregated in 2 or more affecteds in a family 
7,729 SNVs 305 indels 
Predicted damaging 
15,091 SNVs 545 indels 
<3% MAF 
23,660 SNVs 1,342 indels 
Non-synonymous or Splicing 
46,402 SNVs 2,192 indels 
Quality-Filitered Variants 
149,055 SNVs 9,378 indels 
 
 
Table 8. Variants identified in the Parkinson disease discovery cohort. All variants are predicted to be 
nonsynonymous single nucleotide variants (SNV). Chr = chromosome, Ref = reference allele, Alt = alternate allele, 
ExAc Freq = total frequency in Exome Aggregation Consortium. *A single family shared two variants of interest 
(denoted by asterisks) in the same gene. 
Gene 
Symbol 
Chr Position Ref Alt ExAc 
Freq 
Amino Acid Change CADD 
score 
Discovery 
Samples/ 
Families 
Families with 2 or 
more members 
sharing variant 
CBLC 19 45295664 A G 0.0081 NM_001130852:c.A892G:p.M298V 17.0 8/4 2 
 19 45296767 G A 0.0045 NM_001130852:c.G1036A:p.E346K 13.0 3/2 1 
CHAT 10 50824106 C T 0.0095 NM_001142933:c.C8T:p.P3L 4.5 4/2 2 
 10 50863188 G A 0.0075 NM_001142929:c.G1328A:p.R443Q 29.1 4/2 1 
KIF1B 1 10363664 G T 0.018 NM_183416:c.G2421T:p.M807I 4.2 3/2* 1 
 1 10363944 G A 8.17e-06 NM_183416:c.G2701A:p.E901K 14.0 3/1 1 
 1 10364260 A G 0.0061 NM_183416:c.A3017G:p.E1006G 11.3 4/3* 1 
MYLK2 20 30408306 C G 0.013 NM_033118:c.C430G:p.P144A 23.8 7/5 1 
 20 30407387 G A 0.00070 NM_033118:exon2:c.G4A:p.A2T 23.8 2/1 1 
TNK2 3 195594494 C T 0.015 NM_005781:c.G2630A:p.R877H 21.7 11/4 4 
 3 195595212 C T 0.0026 NM_005781:exon12:c.G1912A:p.V6
38M 
29.3 2/1 1 
TNR 1 175355171 T C N/A NM_003285:exon8:c.A1774G:p.T59
2A 
24.2 2/1 1 
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 1 175372714 T G 0.0043 NM_003285:c.A538C:p.N180H 24.5 2/1 1 
 1 175375355 T C 0.0044 NM_003285:c.A496G:p.T166A 13.6 5/3 1 
 1 175375388 A T 7.33e-05 NM_003285:c.T463A:p.C155S 22.0 2/1 2 
TRIM56 7 100731638 C T 0.028 NM_030961:c.C1045T:p.L349F 7.74 6/4 2 
 7 100732376 G A 0.0040 NM_030961:exon3:c.G1783A:p.A59
5T 
10.78 3/1 1 
TOPOR
S 
9 32541880 G C 0.0028 NM_001195622:exon2:c.C2448G:p.
H816Q 
12.1 3/1 1 
 9 32542278 T C 0.017 NM_001195622:c.A2050G:p.N684D 15.0 3/2 2 
 9 32550896 G C 0.0085 NM_005802:exon2:c.C74G:p.S25W 19.6 2/1 1 
 9 32550953 G A 4.50e-05 NM_005802:exon2:c.C17T:p.P6L 22.9 2/1 1 
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Replication cohort 
Clinical characteristics of the 49 familial PD probands in the replication cohort are 
summarized in Table 7. 
 
Rare variants predicted to be damaging in the 8 genes prioritized in the discovery 
analysis were extracted from WES data for the replication cohort. Three genes 
(KIF1B, TNK2, and TNR) that harbored variants of interest (as defined in the 
Methods) in the discovery cohort were also found to have variants of interest in 
the replication cohort (Table 9). One variant in KIF1B (p.E1006G) was observed 
in both discovery and replication samples (3 and 1 samples, respectively). For 
the other 2 replicated genes, distinct variants were identified in the discovery and 
replication cohorts. 
 
 
Table 9. Parkinson disease candidate genes identified through whole exome sequencing. RVIS=Residual 
Variation Intolerance Score (lower percentile corresponds to more mutation intolerant genes). *Asterisks indicate 
variants that were seen in both discovery and replication cohorts. 
 
Gene 
Symbol 
Gene Name Map 
Location 
Gene Ontology Transcript 
Size 
(base 
pairs) 
Genic 
Intolerance 
(RVIS Score 
Percentile) 
No. of 
Variants/ 
Families in 
Discovery 
Cohort 
No. of Variants/ 
Families in 
Replication 
Cohort 
KIF1B kinesin family 
member 1B, 
transcript 
variant 2 
1p36.2 neuron-neuron 
synaptic 
transmission 
7,680 3.93% 3/5 1/1* 
TNK2 tyrosine 
kinase, non-
receptor, 2 
3q29 protein 
ubiquitination 
4,476 14.28% 2/5 2/2 
TNR tenascin R 
(restrictin, 
janusin) 
1q24 neuron-neuron 
synaptic 
transmission; 
regulation of 
synaptic 
transmission 
5,190 20.04% 4/6 1/1 
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In total, the 3 replicated genes were observed to harbor 12 distinct potentially 
functionally relevant variants (Table 10). All 12 variants were confirmed by 
targeted PCR and Sanger sequencing in all relevant samples, and allele 
frequencies obtained from ExAC corresponded to those from 1000 Genomes and 
ESP. Genic intolerance RVIS score percentiles51 and CADD scores46 were 
computed for the retained genes and variants in order to further characterize the 
potential impact of functional mutations at the gene- and variant-level 
respectively. The 3 replicated genes had a mean RVIS score percentile of 12.8% 
(SD=8.2%), and the mean CADD score for the 12 retained variants was 20.4 
(SD=8.7). The calculated RVIS score percentiles fall within ranges that reflect 
purifying selection, or probable greater intolerance for mutations within the gene 
than most genes. Similarly, the computed CADD scores, with the exception of 
one variant (p.M807I in KIF1B), place all of the 12 retained variants at or above 
the 10% most deleterious variants in the human genome, as predicted by a 
comprehensive range of predictions used in the CADD algorithm.
 
 
Table 10. Variants identified in the Parkinson disease candidate genes. Chr = chromosome, Ref = reference allele, 
Alt = alternate allele, ExAc Freq = total frequency in Exome Aggregation Consortium. *Asterisk indicates variant that 
was seen in both discovery and replication cohorts. 
Gene 
Symb
ol 
Chr Position Ref Alt ExAc 
Freq 
Exonic Prediction Amino Acid Change CADD 
score 
Discovery 
Families / 
Replication 
Probands 
KIF1
B 
1 10363664 G T 0.018 nonsynonymous SNV NM_183416:c.G2421T:p.M807I 4.2 2/0 
 1 10363944 G A 8.17e-06 nonsynonymous SNV NM_183416:c.G2701A:p.E901K 14.0 1/0 
 1 10364260 A G 0.0061 nonsynonymous SNV NM_183416:c.A3017G:p.E1006G 11.3 3/1* 
TNK2 3 195594092 G A 5.83e-05 nonsynonymous SNV NM_005781:exon13:c.C2930T:p.A977V 17.8 0/1 
 3 195594494 C T 0.015 nonsynonymous SNV NM_005781:c.G2630A:p.R877H 21.7 4/0 
 3 195595212 C T 0.0026 nonsynonymous SNV NM_005781:exon12:c.G1912A:p.V638
M 
29.3 1/0 
 3 195605390 A G 2.45e-05 nonsynonymous SNV NM_005781:exon8:c.T1088C:p.V363A 25.9 0/1 
TNR 1 175355171 T C N/A nonsynonymous SNV NM_003285:exon8:c.A1774G:p.T592A 24.2 1/0 
 1 175355213 G A N/A stopgain SNV NM_003285:exon8:c.C1732T:p.R578X 36.0 0/1 
 1 175372714 T G 0.0043 nonsynonymous SNV NM_003285:c.A538C:p.N180H 24.5 1/0 
 1 175375355 T C 0.0044 nonsynonymous SNV NM_003285:c.A496G:p.T166A 13.6 3/0 
 1 175375388 A T 7.33e-05 nonsynonymous SNV NM_003285:c.T463A:p.C155S 22 1/0 
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Discussion 
Using WES in a discovery and replication cohort of familial PD patients, we 
detected 12 likely deleterious, rare, exonic variants in 3 genes (KIF1B, TNK2, 
and TNR) that may play a role in susceptibility to PD. All variants were found in 
the heterozygous form, suggesting that they are inherited in a dominant manner, 
as expected from the pedigree structures of the families sequenced, and may 
lead to a disease phenotype either through a gain-of-function, haploinsufficiency, 
or a dominant negative mechanism. 
 
KIF1B, or kinesin family member 1B, is a gene on 1p36.2 that encodes a motor 
protein that transports synaptic vesicle precursors and mitochondria.145-148 
Mutations in KIF1B were linked with Charcot-Marie-Tooth disease type 2A 
(CMT2A);145 however, a recent study more conclusively implicates the nearby 
MFN2 gene in CMT2A.149 Three rare, nonsynonymous variants in KIF1B were 
found in this study, including one variant (p.E1006G) that was present in both the 
discovery and replication cohorts. The variants do not overlap known KIF1B 
protein domains in Ensembl, although they do all cluster on the most 3 prime 
coding exon of the gene. Further work is needed to confirm the effects of these 
variants on protein structure and/or function. 
 
TNK2 encodes for a non-receptor tyrosine kinase (activated CDC42 kinase 1) 
that is important for cell growth, survival, and migration. Studies suggest that 
TNK2 is involved in synaptic function and plasticity,150-152 and a recent report 
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suggests that mutations in the gene may cause autosomal recessive infantile 
onset epilepsy.153 Other studies exploring the role of TNK2 in cancer have 
established links between the TNK2 protein and the epidermal growth factor 
receptor (EGFR).154,155 In the discovery and replication cohorts, 4 unique rare 
nonsynonymous TNK2 variants were identified. One variant (p.V363A) is found in 
the EGFR inhibitor Mig-6 domain (IPR021619, PF11555). Binding of Mig-6 to the 
kinase domain of EGFR inactivates the receptor, which suggests that this domain 
in the TNK2 protein may also be important for appropriate regulation of its 
function. 
 
TNR, or tenascin R, encodes an extracellular matrix glycoprotein only found in 
the central nervous system.156 Tenascin R is thought to be involved in neurite 
growth, neural cell adhesion, and sodium channel functioning.157,158 Of the 6 
unique variants prioritized in TNR, 5 were found only in the discovery cohort as 
rare nonsynonymous variants. One variant (p.R578X) was found only in the 
replication cohort and results in the addition of a stop site at position 578 of a 
1358 amino acid protein. This variant, along with one other variant (p.T592A), are 
found in the fibronectin-3 domain (IPR003961) of the protein, which is important 
for cell surface binding. 
 
Variants from the discovery analysis present in the 5 genes lacking evidence of 
replication (CHAT, CBLC, MYLK2, TRIM56, and TOPORS) are listed in Table 8. 
While some or all of these genes may represent false positives, differences 
98 
 
between the discovery and replication analysis (captures, sequencing 
chemistries, bioinformatics pipelines, allele frequency threshold, etc.) may have 
prevented replication. Additionally, some genes may not have been prioritized to 
look for evidence of replication due to differences between the two captures and 
other possible batch effects in the discovery phase limiting the effectiveness of 
the across families filter. 
 
Unlike previous studies focused on a single large pedigree or extensive datasets 
of unrelated individuals, our blended approach leveraged a well-characterized set 
of moderately-sized families and an additional set of unrelated familial probands. 
A major advantage of this study is that both the discovery and replication cohorts 
only included familial PD cases, unlike many other studies where discovery 
samples are in families and replication cohorts include sporadic cases. Families 
with multiple affected members are more likely to be enriched for causative, 
moderately rare variants having a modest or large effect size.  By requiring 
variant segregation within a family, we limited the number of false positives in the 
discovery phase. Furthermore, our two-phase study design decreases the 
chance of false positives and thus increases the likelihood that the 3 candidate 
genes identified in this study are truly involved in PD etiology, though further 
replication in other datasets is warranted.  
 
Another strength of the study is that locus heterogeneity could be explored both 
within and between families. In the discovery analysis, we required variants to 
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segregate with at least two PD cases in a family, thereby allowing any remaining 
cases in the family to potentially have a distinct genetic or environmental cause. 
Our experimental design contrasts with recent efforts that employ sequencing 
approaches in large family pedigrees to identify variants with fully penetrant 
effects and therefore responsible for strictly Mendelian PD; this category of 
variants appears to account for rare causes of PD.128,129,133 While our study 
design allows for detection of such mutations, the employed strategy also permits 
the discovery of rare variants with intermediate penetrance, such as LRRK2 
G2019S159 and mutations in GBA.160 Since 10-20% of PD patients report having 
at least one first-degree relative affected by PD,161-163 it is possible that variants 
of this class remain a major contributor to PD heritability. Complex genetic 
etiology has been previously observed in PD; for example, reports have shown 
that in some families segregating Mendelian forms of PD (SNCA or LRRK2 
positive families), not all affected family members carry a mutation.121,164,165 Our 
study is also robust to detect interfamilial allelic heterogeneity, or unique variants 
in the same gene segregating in different families.   
 
One limitation of our approach was that larger genes might be prioritized by 
chance because of their size rather than due to the enrichment of rare functional 
variants associated with PD. Exome sequencing by design also misses possibly 
important variation in intronic and regulatory regions, as well as forms of 
structural variation. Use of the GO filter to focus on pathways of interest might 
have excluded important genes that were either poorly annotated or in pathways 
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thus far not associated with PD. The GO filter used, as seen in Figure 14, 
narrowed the number of variants under consideration from 6,635 to 228 SNVs, 
ultimately prioritizing 21 variants across 8 genes for further study. Had the GO 
filter not been applied, the 6,635 SNVs would have only been narrowed to 300 
SNVs (87 genes) using the across families filter. Future studies with larger 
sample sizes could employ formal gene set enrichment analysis to bypass the 
potential limitation of relying on pre-specified pathways for variant filtering. 
 
Summary 
In summary, we employed a two-stage strategy to identify and replicate genes 
that may harbor rare variants contributing to PD susceptibility. Both the discovery 
and replication samples were comprised of familial PD patients, who may be 
more likely to segregate relatively rare variants of larger effect on disease risk. 
The 3 genes nominated in this study warrant further evaluation for their potential 
role in PD pathophysiology.  
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CHAPTER III: X-LINKED ATAXIA DEMENTIA 
 
Introduction 
X-linked ataxia dementia (XLAD), also known as X-linked spinocerebellar ataxia 
type 4, is an extremely rare neurodegenerative disorder. During their childhood, 
affected individuals develop ataxia, or uncoordinated movement. Dementia 
occurs later in life, along with variable onset of upper motor neuron disease.  
Increasing motor, emotional, and mental instability occurs throughout the second 
through fifth decades of life, with death typically in the sixth decade. Moderate 
phenotypic variability is observed in affected males, and carrier females 
sometimes show a milder phenotype including cognitive and motor abnormalities. 
The disease appears to segregate in an X-linked pattern in the one kindred ever 
described with this syndrome (Figure 15). Clinical and laboratory investigations in 
this family indicate cerebellar and pyramidal system involvement with severe 
cerebral cortex deficiencies.166 
 
 
 
 
Figure 15. Simplified pedigree for the X-linked ataxia dementia family. Whole genome sequencing was performed 
on individuals in red. WES = whole exome sequencing; GWAS = Omni1-Quad Genome Wide Association Study Array; 
? = male at risk for XLAD but of unknown disease status due to young age at time of assessment 
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Other ataxia-dementia syndromes such as olivopontocerebellar atrophy, 
Gerstmann-Straussler-Sheinker disease, and adrenoleukodystrophy were all 
considered but ruled out in this family. Two other reports exist of ataxia and 
dementia both segregating in a X-linked manner, but affected members of those 
families have compounding extrapyramidal symptoms. There are also X-linked 
syndromes displaying either ataxia or dementia but not both reported in the 
literature.167,168  
 
Previous linkage studies using microsatellite markers on the X chromosome were 
conducted (unpublished data). In the most recent study, microsatellite markers at 
approximately 5 cM intervals were used, all females were classified as 
unaffected, and penetrance was set at 95%. After genotyping of a second set of 
microsatellite markers to narrow the interval, a LOD score of 5.29 was obtained 
in the region Xq21.33-q23. To rule out fragile X-associated ataxia, individuals III-
12, IV-8, and IV-11 were also tested for fragile X using PCR; all 3 samples were 
normal. (Figure 16) 
 
 
Figure 16. X-linked ataxia 
dementia family structure and 
haplotype analysis. Analysis and 
figure generation by Jill Rosenfeld 
(unpublished data). Parentheses 
indicate inferred genotypes. The 
regions of a narrowed bar for 
individuals II-6, III-10, and III-14 
indicate unknown phase, while all 
other narrowed bars indicate 
regions of recombination. 
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Further genotyping of two distantly related affected males (Figure 15, III:15, 
IV:11) and two unaffected males (IV:10, IV:12) on an Illumina Omni1-Quad array 
narrowed the region of interest to 19Mb and ruled out a large CNV. Over 100 
genes are contained in this interval. 
 
WES was conducted for 3 individuals (III:15, IV:11, IV:12) in a previous study 
(Agilent SureSelect Human X Chromosome Demo Kit, 75bp paired-end 
sequencing, Illumina GAIIx, BWA, SAMtools). Five SNVs were identified that 
were present on the disease haplotype but not present in dbSNP. Three of these 
variants were identified either in the pilot 1 dataset for the 1000 Genomes Project 
or in the genotyping results from 2000 female controls; due to the rarity of the 
disease, it was hypothesized that any causative variant would be completely 
novel, and thus the 3 variants were excluded from further study. The remaining 
two SNVs did not have an obvious mechanism of disease causation. Four short 
indels also were identified on the disease haplotype, but all were present in the 
1000 Genome Project. (Table 11)
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Table 11. X-linked ataxia dementia whole exome sequencing variants on 
the disease haplotype and not present in dbSNP. 
Chr Position Ref Fam Gene FunctionGVS 
1000 
Genomes 
# 
control 
chrs 
X 99992932 G A NOX1 
coding-
synonymous 0/182 2/4000 
X 102833316 G A none intergenic 2/182 - 
X 105083643 A T NRK 
intron (39 bp 
from exon) 0/182 0/4000 
X 102932576 G A PLP1 utr-3 1/182 17/4000 
X 107221681 C G ATG4A 
utr-5 (31 bp 
from start 
codon) 0/182 0/4000 
 
In the present study, 2 individuals (III:10, IV:11) were chosen for WGS in order to 
expand the search space for rare variants that may be involved in causing the 
disease. 
 
Materials and methods 
Subjects 
The simplified pedigree for the XLAD family is depicted in Figure 15. All subjects 
submitted written consent, and the study was approved by the Indiana University 
IRB. 
 
The Agilent SureSelectXT2 Library Prep Kit and Illumina HiSeq2000 (Flowcell v3, 
TruSeq Cluster Kit v3, TruSeq SBS v3) were used to generate 100 bp paired end 
sequencing data. Paired end alignment was performed to the GRCh37 reference 
genome with BWA v.0.5.10, and duplicates were marked using Picard v.1.74. 
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GATK v.2.3-4 was used for indel realignment, base call quality score 
recalibration, multi-sample variant calling (Unified Genotyper), and VQSR. 
Bedtools v.2.19.1 was used for coverage analysis of coding exons (defined by 
UCSC coordinates) within the region of interest.  Variants were annotated by 
ANNOVAR and the recently-developed CADD program. 
 
High-quality variants located in the region of interest that were novel (not present 
in 1000 Genomes, the Exome Sequencing Project, and dbSNP137) and located 
in the region of interest were retained. All variants identified in an exonic, 
splicing, UTR, or regulatory region were retained. Variants of interest were 
visually inspected using IGV v.2.3.34. The entire region was also visually 
inspected using IGV for alignment issues (regions of soft-clipping, unmapped 
pairs, abnormal pair orientations) that may point to a small to medium-sized 
structural variant. 
 
Results 
The average transition/transversion ratio for exonic variants and all variants was 
3.10 and 2.12 respectively, and the percentage of variants found in dbSNP137 
was 98.98%. Mean autosomal coverage was 27X, and 97.5% of autosomal 
regions were covered >8X. 
 
Coverage analysis revealed that very few small intervals of coding exons within 
the region of interest were not covered at all or had low coverage (Table 12). 
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Table 12. X-linked ataxia dementia whole genome sequencing coverage 
analysis. DP = sequencing depth; bp = base pairs 
Sample No Coverage Total 
[Average Interval] 
Low Coverage (DP<5) Total 
[Average Interval] 
III:10 15bp [5bp] 12bp [6bp] 
IV:11 48bp [24bp] 261bp [15bp] 
 
There were 7,901 variants identified in the region of interest. Of these, 5,798 
were heterozygous in the mother and hemizygous in the son, and 505 of these 
were not observed in 1000 Genomes, the Exome Sequencing Project, and 
dbSNP137. Variants were retained if they were found in an exonic, splicing, UTR, 
or regulatory region. Using these criteria, 22 variants (3 SNVs and 19 indels) 
were retained, all of which were located in UTR (Table 13) or regulatory regions. 
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Table 13. X-linked ataxia dementia whole genome sequencing variants 
identified in untranslated regions (UTR). Variants listed by decreasing CADD 
c-score value. *All variants are in the 3’-UTR except MORF4L2 (in 5’-UTR). Chr = 
chromosome, Pos = position (build hg19), Ref = reference allele, Alt = alternate 
allele, SNV = single nucleotide variant, DEL = deletion, INS = insertion 
Chr Pos Ref Alt Type Gene C-Score 
X 103045920 G A SNV PLP1 10.63 
X 102930671 TA T DEL MORF4L2 9.853 
X 100350299 TGC T DEL TMEM35 4.265 
X 106313096 TA T DEL RBM41 3.451 
X 101913597 TA T DEL GPRASP1 0.534 
X 105881497 C CT INS CXorf57 0.325 
X 102941052 TC T DEL MORF4L2* 0 
 
The PLP1 (associated with Pelizaeus-Merzbacher disease, which includes 
childhood ataxia and cognitive impairment) variant was previously identified in 
the WES experiment but was ruled out when genotyped in control chromosomes. 
Further examination at CIDR identified the same variant in two males affected 
with a common disease sequenced with the same capture as the XLAD subjects. 
All other variants have not to date been identified in other datasets. 
 
Upon visual inspection with IGV, no regions were found with an obvious 
structural variant shared in the mother and son. 
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Discussion 
The magnitude of the linkage signal at Xq21.33-q23 strongly suggests that the 
variant that causes XLAD exists in this interval. Both WES and WGS, however, 
have not identified an exonic, and putatively functional variant within this region 
that segregates in a X-linked recessive manner. Together, the WES and WGS 
experiments suggest that adequate coverage has been achieved over the entire 
region of interest (Table 12). There may be variation within the interval however 
that is difficult to assess with sequencing methods (e.g. areas of repetitive 
sequence). Study designs not reliant on the current methods of sequencing 
would be required to detect these variants. 
 
A number of novel variants in predicted non-coding regions of the X chromosome 
agree with the hypothesized segregation pattern (Table 13). Although the 
severity of phenotype suggests that the causative variant is within a coding 
region, a non-coding variant may also lead to the disease. For instance, changes 
in promoter regions or enhancers can affect gene transcription, while UTR 
sequence alterations can influence the regulation of translation. Possible links 
between both 5’ and 3’-UTRs and diseases including X-linked Charcot-Marie-
tooth disease, Fragile X syndrome, epidermolysis bullosa simplex, and a number 
of other diseases have been suggested.169 Targeted mutagenesis and 
subsequent examination of translation efficiency could be utilized to study the 
variants in Table 13. As noted by Ward and colleague however,170 landmark 
studies linking non-coding variants to some diseases required extensive 
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experimental follow-up, and rigorous study will be required to confirm the 
association of any variants identified in this study with XLAD pathogenesis.  
 
Another possible reason for a lack of a positive exonic finding thus far may be 
due to limitations in current methods and data sources for annotation. Thus, a 
variant nominated in the WGS data actually may be a coding variant that has not 
been assigned to a gene yet. As annotation sources improve over time, periodic 
re-examination of the WGS data using the existing pipeline is warranted. A 
review of annotations for non-coding variants could be relevant as well, 
especially as systematic efforts such as the ENCODE Project171 and the 
Roadmap Epigenomics Mapping Consortium172 continue to release data. 
 
This work also has not conclusively ruled out a structural variant as a cause for 
the disease. At the time of the study, algorithms to effectively detect and 
conclusively call medium-sized structural variants were still in development. 
Because automated methods for detecting structural variation are not yet 
optimized, we manually reviewed the entire 19 Mb region of interest for evidence 
that a structural variant might be present (as described in the Methods), but 
found no signs at this time that there is a structural variant shared in the mother 
and son. Future studies in XLAD could focus on structural variants, since variants 
such as simple repeat expansions have been clearly linked with several 
neurological diseases, including Fragile X173-175 and Friedreich’s ataxia.176 
Emerging bioinformatics tools for application to HTS could be used, although 
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methods other than sequencing might be warranted due to the difficulty of 
designing sequencing baits and accurately calling sequencing variants in highly 
repetitive regions. Another option for future study is to investigate whether the 
insertion of novel sequence could lead to the disease. This type of variation 
would require a very different analysis pipeline, most likely including 
computationally-intensive de novo assembly or even different sequencing options 
(e.g. selecting a technology that will produce longer read lengths).177 Additional 
members of the family could be screened for identified candidate structural 
variants, and molecular studies to characterize the potential role of segregating 
variants should be conducted.  
 
Summary 
A series of genetic study designs have been applied in a single kindred 
segregating a rare neurodegenerative disease. Initial linkage studies pointed to a 
strongly significant interval on the X chromosome, but genome-wide genotyping 
and WES failed to identify a promising candidate gene. Further WGS has not 
identified a clearly causative variant for this region. A few variants in UTR and 
regulatory regions are possible candidates for further validation and exploration 
of involvement in disease causation. Although preliminary visual inspection was 
conducted of the region of interest, further work remains to identify structural 
variants. Additional alignment and calling algorithms can be used to circumvent 
potential biases in the current bioinformatics pipeline used. 
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CONCLUSION 
 
Within the field of family-based sequencing, there are many study designs that 
can help elucidate the genetic basis of both rare and complex diseases. In the 
present study, WES was applied to both familial IA and PD, and both WES and 
WGS were employed to study a family with XLAD. For IA, we used WES of a 
small set of densely affected families to describe considerations for other WES 
studies in complex disease, including use of family and clinical data, sources and 
definitions for gene and variant annotations, interpretation of in silico predictions, 
and more. Our PD WES study was a two-stage design, blending the use of 
moderately-sized families and an independent set of familial probands that 
allowed for the exploration of locus heterogeneity within and between families. 
The XLAD study presented an opportunity to compare and combine WES and 
WGS results, and although a definitely causative gene was not identified, 
important groundwork has been laid for future studies. As HTS technology and 
analysis methods improve and decrease in cost and labor intensiveness, WGS 
will likely supplant WES due to lower bias and broader coverage.30 Thus, 
experience with applying this technology to families will become increasingly 
important. 
 
Advantages of family-based sequencing studies 
There are several advantages for using familial data for sequencing studies. 
First, such studies are enriched for samples that are actually linked by a genetic 
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cause of disease178,179 and can control for type 1 error rates due to population 
stratification.180 Given the difficulty of narrowing down the enormous number of 
variants identified in WES and WGS, sequencing multiple individuals per family 
can dramatically aid the filtering process as demonstrated in the current work. 
Furthermore, family-based sequencing can somewhat offset the expense of 
following-up a large number of candidate variants, since putative causative or 
protective alleles can first be genotyped in other family members to confirm or 
refute segregation. Such segregation studies will be an obvious next step in the 
follow-up of the variants identified in our IA, PD, and XLAD families. Unexpected 
patterns of segregation can be checked against possible locus or allelic 
heterogeneity, or even environmental causes for the disease. Furthermore, 
although not explored in the present work, homozygosity mapping of familial 
sequencing data can also be an effective method for determining the genetic 
basis of an autosomal recessive disease.30 
 
Stringent quality control measures for HTS are critical, and family-based 
sequencing studies have the benefit of additional sources for quality metrics.67,178 
Careful examination of expected and computed pedigree structure can verify that 
samples are labeled correctly and can identify cryptic relatedness. It is not 
uncommon to find individuals related to one another in the same study, even for 
the larger studies being conducted with ‘unrelated’ cases; such relatedness can 
easily confound the results of even a well-designed study. Additionally, data from 
multiple family members can improve variant calling, especially for structural 
115 
 
variation. In fact, some variant detection algorithms like PennCNV,181 FamSeq,182 
PolyMutt183 already make use of familial information. Since many types of 
structural variants have not been ruled out for all our IA, PD, and XLAD families, 
future studies should utilize these tools and emerging ones. As was mentioned 
for XLAD, certain types of structural variation have not been completely ruled out 
as the causative mutation in the family. 
 
Caveats for family-based sequencing studies 
While there are many advantages to using familial sequencing data, there are 
some important caveats as well. If using statistical association tests, particular 
care must be taken to account for relatedness, or special algorithms designed to 
incorporate pedigree information should be used.184,185 Since increased 
computational resources are required for incorporating pedigree information, 
these programs have been slower to develop. For these tests or for manual 
filtering, as was used in the studies presented in this work, researchers must be 
aware that assumed inheritance models may not actually reflect genuine allelic 
inheritance. Studies may be broadly designed to examine multiple inheritance 
models, as was done for the FIA and PD studies presented. 
 
Great attention must be paid toward careful phenotyping before assigning strict 
inheritance hypotheses, especially for complex diseases. As demonstrated in the 
FIA study, these considerations are important for designating affected and 
unaffected status, as well as assessing for reduced penetrance and 
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heterogeneity. For instance, careful examination of smoking and hypertension 
data for individuals is critical when studying IA genetics, given the important 
contribution of both environmental risk factors to the disease.86 Similarly, 
information about carriers of known mutations like LRRK2 G2019S or individuals 
whose clinical history points to exposure to certain chemical agents or a history 
of head injury should be factored into variant segregation analysis in PD. 
 
Additionally, not all disease models are best studied through use of family data. 
For diseases with a low sibling recurrence risk ratio like autism, it may be more 
advantageous to study unrelated affected individuals rather than familial 
samples,179 unless large pedigrees with high familial aggregation are used.178 
Finally, for studies assessing de novo mutations that lead to drastically reduced 
fitness, the benefit of additional segregation analyses may not be present. 
 
Future genetic studies in IA, PD, and XLAD 
Our studies in IA, PD, and XLAD illustrate both the opportunities and challenges 
of family-based HTS. Candidate variants and genes have been identified in all 
three studies, although much work remains to fully characterize these variants 
and confirm their role in disease pathogenesis. Evidence from aneurysmal 
expressions studies in IA and a replication WES cohort in PD serve as 
preliminary steps in this effort, and further population genetic study designs for IA 
and PD are underway. Collaborative efforts to combine sequencing data with 
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other groups may yield further evidence toward the genes nominated in this 
work. 
 
Although current efforts in our group are limited to genomic sequencing, we 
expect to utilize other high-throughput designs (Table 1 and Figure 17) in the 
future. A future challenge will be to integrate various ‘omic’ approaches with more 
targeted molecular studies to get a more complete picture of disease 
pathogenesis in individuals and populations. Even more questions exist about 
appropriate study designs for data integration, but the need to draw conclusions 
across many types of high-throughput data is well recognized.186 
 
 
 
Figure 17. Data integration of high-throughput ‘omics.’ SNP = single nucleotide polymorphism, CNV = copy 
number variant, LOH = loss of heterozygosity, TF = transcription factor, bs = binding site, Me = methylation, 
CSF = cerebrospinal fluid. Ritchie et al, 2015.186 
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Molecular characterization of any candidate gene or variant is crucial. While the 
specific experiments utilized will largely depend on the gene of interest, there are 
general approaches and tools that could be applied broadly. Specifically, genome 
engineering experiments187 can make targeted alterations to the genome that 
reflect the variants identified, allowing the researcher to then observe 
transcriptional and translational efficiency; stability, localization, binding, and 
functions of resultant proteins; and other potential effects of the sequence 
perturbations in cellular and animal models. 
 
When designing such studies, characteristics of the disease being studied are 
important to consider. For instance, the phenotype of IA development and 
rupture may only be replicated in tissue models with careful hemodynamic 
control. Examination of the effects of a sequence alteration on a protein in 
endothelial cells may not be enough to model the complementary effects of 
vascular smooth muscle cells and fibroblasts, as well as how the overall vascular 
structure responds to hemodynamic stress or toxins introduced systemically from 
smoking. Additionally, while a possible genetic link has been established 
between IA and extracranial aneurysms,109 the particular properties of 
intracranial arteries as opposed to their extracranial counterparts should be 
considered when constructing a model. Established differences include the 
distribution of elastic components, the thickness of layers of the arterial wall, and 
the perivascular support of cerebrospinal fluid for cerebral arteries.188 
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In PD, studying both neuronal and glial cells may be important to recapitulate the 
phenotype. Multiple model systems may need to be employed, as current models 
do not individually reproduce all aspects of PD. In fact, a current obstacle in PD 
animal model research is that even the observation of an aggregation of alpha-
synuclein, a hallmark histopathological marker of PD, does not always 
correspond to a quantifiable motor phenotype in animal models. Additionally, 
motor symptoms in animal models do not completely translate to motor 
manifestations in humans affected with PD. Models also frequently do not 
recapitulate the common non-motor symptoms of PD, including sleep 
disturbances, dysfunction of the gastrointestinal system, and depression.189 
 
Since specific brain regions have not been implicated in XLAD other than through 
typical clinical symptom manifestations and their localizations, future studies in 
XLAD may need global studies of transcription and translation in the brain before 
diving into targeted study of a particular cell type or mechanism. Finally, IA, PD, 
and XLAD are all complicated by the fact that they are intracranial, which limits 
the accessibility to both affected and unaffected human tissue. 
 
Potential clinical applications of sequencing findings in IA, PD, and XLAD 
Family-based sequencing studies hold great promise for gene discovery in these 
three diseases, but the ultimate goal for this research is to advance the biological 
understanding of the disease that is necessary for benefiting patient care and 
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outcomes. As demonstrated in Figure 18, translation of sequencing findings to 
the clinic can take many forms.  
 
Figure 18. Translation of sequencing findings to clinic. Adapted from 
McCarthy et al, 2008.190 
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When the role of a particular gene in IA or PD has been confirmed, functional 
assays may be designed to review other variants identified in the gene by other 
research groups or in the clinic more efficiently. As noted by those studying 
BRCA1 and BRCA2, two genes known to be involved in multiple cancers, 
functional assays have been valuable in systematically determining whether a 
rare VUS is functional.191,192 They do note that the multifaceted function of each 
gene and still imperfect knowledge of the pathophysiology behind each cancer 
means that multiple functional assays may be necessary to characterize a 
variant, and that positive or negative tests do not always translate directly to 
developing or not developing the cancer. Nevertheless, a growing database of 
genetic variation and potential mechanisms for disease in IA and/or PD would be 
valuable for translating sequencing findings to clinical practice. 
 
For IA, we believe our studies will ultimately help us to better ascertain the risk of 
developing or rupturing an IA in a family. Given that fatality from IA rupture and 
resultant SAH is estimated between 25-35% in high-income countries and almost 
50% in other countries,84 better risk prediction models based on identifying high-
risk patients clinically (e.g. family history of IA or SAH, smoking and/or 
hypertension, etc.) and combining the clinical information with a genetic profile 
are warranted. Understanding the biological basis behind aneurysm formation 
and rupture may also lead to therapeutic interventions that could help predict IA 
formation or rupture, and possibly halt or reverse the progression of the disease 
process. Such therapeutics could ultimately replace deficient protein or 
123 
 
chemicals, inactivate mutant substrates, increase or decrease gene expression, 
or possibly even introduce corrected sequence. Targeted drug delivery may 
serve as the major obstacle for a therapeutic agent taken systemically, although 
localized application may be possible during clinically-advisable neurosurgical 
clipping of IAs. If intracranial vasculature can still be accessed by a systemic 
therapy that has little harm on extracranial tissues, and the effects on extracranial 
vasculature in particular can be characterized, then systemic therapeutics may 
be feasible. Given the significant morbidity and mortality of this disease, the risk-
to-benefit ratios of increased screening, monitoring, and/or intervention may be 
more palatable to high-risk patients and their clinicians. 
 
In PD, no therapeutic intervention thus far is effective at neuroprotection at an 
early stage in the disease, and many current treatments also have severe side 
effects.193 For instance, the gold standard of levodopa therapy is only efficacious 
without major side effects for 4-6 years.193 Basic gene discovery projects like 
ours are necessary in order to provide novel therapeutic targets, but also to be 
able to offer early detection and monitoring of the disease progression. They may 
also provide new insights into other neurodegenerative diseases. Still, if findings 
from sequencing studies like ours only contribute to better risk prediction, 
diagnosis, and prognosis, they will serve less to improve clinical management of 
this incurable disease and more to fuel better designed studies to discover 
effective therapeutic interventions. Such PD therapies may assist in restoring 
neurochemical balance, supporting fragile dopaminergic neurons, removing 
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buildup of toxic substances, and addressing other changes that have been noted 
in PD pathophysiology. 
 
Finally, confirming the genetic cause of XLAD could potentially offer more options 
for management for this currently incurable disease. With the appropriate cultural 
and ethical caveats, such as those suggested for genetic screening in individuals 
of Ashkenazi Jewish descent,194 reproductive counseling and general carrier 
screening could be employed in this family. Future studies centered on the 
implicated gene, pathway, or other biological mechanism may offer targets for 
halting or even reversing the neurodegenerative process for future descendants 
in the family. Although this disease has only been reported in one family thus far, 
identification of a causative genetic mechanism in this family could also enhance 
our knowledge of the intersection of ataxia and dementia, both devastating 
symptoms of many other neurological disease processes. 
 
Challenges of moving toward everyday genomic medicine 
While not directly addressed in our research findings, our work and others195-197 
have raised some important considerations for the adoption of HTS into clinical 
settings. Much enthusiasm toward clinical HTS applications has been generated 
from some successful applications of WGS and WES in the clinic, especially in 
relation to rare diseases.198,199 At the time of this work, the President of the 
United States unveiled a precision medicine initiative designed to funnel $215 
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million into researching and applying genomics in clinical care. Despite this 
recognition of the potential of clinical genomics, concerns include how clinically 
actionable variants are, the infrastructure and logistics required, and provider and 
patient expectations and readiness for genomic medicine. Such questions are 
relevant to downstream findings from our studies, as well as the numerous other 
HTS studies being conducted on a host of rare and complex diseases. 
 
Clinical utility of variants associated with disease 
Our gene discovery projects are currently focused on identifying any variant 
associated with disease. In clinical applications, however, genomic variants must 
be stratified to facilitate their incorporation into practice (Figure 19). For instance, 
it is recognized that certain genetic variants have well-described effects on a 
patient’s response to certain medications; knowledge of a patient’s 
pharmacogenomic profile is thus clinically actionable.200 Variants that may alter 
management of disease are also prevalent in cancer, where precision genomics 
is being employed to subtype cancers, determine prognoses, select drug 
regimens, and more.201 
 
In some cases, knowledge that a patient carries a variant does little more than 
confirm the diagnosis of a disease and does not alter management at all. One 
such notable case is with sickle cell disease, for which the molecular basis of the 
disease has been known since the 1950’s. Vernon Ingram himself, who 
demonstrated the amino acid substitution critical for sickle cell disease, declared 
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that “the discovery of the molecular basis of the disease…was of limited benefit 
to the patient population.”202 Similarly, the genetic etiology of Huntington’s 
disease was established in the early 1990’s,203 but no curative treatment 
currently exists. Still, some research suggests that predictive testing for 
Huntington’s disease, regardless of the risk profile obtained for an individual, may 
improve the person’s psychological well-being.204 
 
In other fields, there are proven risk variants, but the small or unknown risk to an 
individual patient may mean that no clinical action is warranted. For instance, the 
APOE ε4 allele is the most prevalent risk factor for sporadic Alzheimer’s disease, 
yet not all individuals carrying the allele develop the disease while some without 
the allele do, and no therapeutic interventions to date have been successfully 
created based on knowledge of this risk variant.205  Finally, the largest category 
of genomic variants includes all those that have been identified through human or 
animal studies, but the effect of the variants have not been confirmed or 
characterized. Such variants, such as those identified in our studies in IA and 
PD, are deposited in public databases and the literature in order to advance 
scientific research, but these information sources are also queried by geneticists, 
commercial developers of genetic products, and increasingly engaged patients. 
As previously mentioned, VUS are abundant in genomic research currently, and 
it is unclear how patient expectations and clinical practice may change in 
response to returned reports of these types of variants.  
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Figure 19. Stratification of genomic disease variants. 
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Although many preach that genomic testing is just another type of clinical test, 
there are few arguments that the logistics of widespread adoption of genomic 
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clinics, and other access points for patients and healthcare providers. Given the 
highly identifying nature of genomic data, great care must be taken to ensure the 
security of any data storage and transfer. Infrastructure needs also include 
modifications to the Clinical Laboratory Improvement Amendments (CLIA) 
environment, establishing practical reimbursement schemes, and other legal, 
political, and regulatory necessities.207 
 
Considerations for providers and patients 
Beyond technological infrastructure, much debate exists about whether 
healthcare providers and patients are ready for genomic medicine. Many believe 
that there is currently inadequate genomics education in the health 
professions,195,208-210 leading to a prohibitive level of physician discomfort in 
interpreting and applying genomic information in everyday practice.211,212 The 
genetics community is working to suggest what type of results to return and 
when,213-215 but there is currently no gold standard across medical specialties. 
The number of potential incidental findings, findings whose implications may 
change quickly over time as research advances, is unprecedented in genomic 
data. 
 
Many advocate for patient choice in the return of genomic data, and recently 
developed direct-to-consumer options encourage active patient engagement but 
raise concerns in the clinical and research communities.216-219 Studies have 
shown that most patients would prefer to have all or most information returned, 
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even if such data is not deemed actionable by the clinical genetics 
community.220,221 This poses the question of whether the return of some 
information, such as VUS, may actually cause more harm than good. Such harm 
could be psychological or, in the case of unnecessary testing and treatment, 
physical. Additionally, there will likely be increased strain on healthcare 
resources, as time, labor, and money are redirected toward pre- and post-test 
counseling and following up potential findings. The released genetic information 
may also have implications for family members of the patient, which raises issues 
about informed consent and counseling of entire families, especially in regard to 
pediatric patients. While efforts to provide genomics education to the public are 
beneficial,222 it is unlikely that these initiatives will be enough to ensure that 
genomic data are appropriately received, internalized, and utilized. As a result of 
questions about value, potential harm, cost, and feasibility, some advocate for 
the limited return of select incidental findings to particular patient populations 
based on disease state223 or the stage of lifespan and purpose of the test.224 
 
Genomics holds incredible potential to revolutionize our knowledge of disease, 
as well as the practice of medicine in general. Our understanding of the genetic 
basis behind diseases like IA, PD, and XLAD will undoubtedly advance through 
different high-throughput technologies. The many advantages of family-based 
sequencing studies in both rare and complex disease position them to become 
strategies of choice for gene discovery projects, with important caveats to ensure 
appropriate study design and molecular characterization of implicated genes. 
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Ultimately, such research should be directed toward improved and novel clinical 
applications. Much work remains, however, to ensure that unintended 
implications of the widespread adoption of genomic medicine are premeditated 
and thoughtfully handled.  
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